1
|
Almairac F, Parker D, Mondot L, Isan P, Onno M, Papadopoulo T, Fontaine D, Verma R. Improvement of diffusion tensor imaging-based tractography by free-water correction in nonedematous gliomas: assessment with brain mapping. J Neurosurg 2024:1-11. [PMID: 38626474 DOI: 10.3171/2024.1.jns23568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 01/29/2024] [Indexed: 04/18/2024]
Abstract
OBJECTIVE The free-water correction algorithm (Freewater Estimator Using Interpolated Initialization [FERNET]) can be applied to standard diffusion tensor imaging (DTI) tractography to improve visualization of subcortical bundles in the peritumoral area of highly edematous brain tumors. Interest in its use for presurgical planning in purely infiltrative gliomas without peritumoral edema has never been evaluated. Using subcortical maps obtained with direct electrostimulation (DES) in awake surgery as a reference standard, the authors sought to 1) assess the accuracy of preoperative DTI-based tractography with FERNET in a series of nonedematous glioma patients, and 2) determine its potential usefulness in presurgical planning. METHODS Based on DES-induced functional disturbances and tumor topography, the authors retrospectively reconstructed the putatively stimulated bundles and the peritumoral tracts of interest (various associative and projection pathways) of 12 patients. The tractography data obtained with and without FERNET were compared. RESULTS The authors identified 21 putative tracts from 24 stimulation sites and reconstituted 49 tracts of interest. The number of streamlines of the putative tracts crossing the DES area was 26.8% higher (96.04 vs 75.75, p = 0.016) and their volume 20.4% higher (13.99 cm3 vs 11.62 cm3, p < 0.0001) with FERNET than with standard DTI. Additionally, the volume of the tracts of interest was 22.1% higher (9.69 cm3 vs 7.93 cm3, p < 0.0001). CONCLUSIONS Free-water correction significantly increased the anatomical plausibility of the stimulated fascicles and the volume of tracts of interest in the peritumoral area of purely infiltrative nonedematous gliomas. Because of the functional importance of the peritumoral zone, applying FERNET to DTI could have potential implications on surgical planning and the safety of glioma resection.
Collapse
Affiliation(s)
- Fabien Almairac
- 1Department of Neurosurgery, Pasteur 2 Hospital, University Hospital of Nice, France
- 2Clinical Research Unit UR2CA team PIN, French Riviera University, Nice, France
| | - Drew Parker
- 3Department of Radiology, Diffusion and Connectomics in Precision Healthcare Research Lab, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Lydiane Mondot
- 4Department of Neuroradiology, Pasteur 2 Hospital, University Hospital of Nice, France
- 5Clinical Research Unit UR2CA team URRIS, French Riviera University, Nice, France; and
| | - Petru Isan
- 1Department of Neurosurgery, Pasteur 2 Hospital, University Hospital of Nice, France
- 2Clinical Research Unit UR2CA team PIN, French Riviera University, Nice, France
| | - Marie Onno
- 1Department of Neurosurgery, Pasteur 2 Hospital, University Hospital of Nice, France
| | | | - Denys Fontaine
- 1Department of Neurosurgery, Pasteur 2 Hospital, University Hospital of Nice, France
- 2Clinical Research Unit UR2CA team PIN, French Riviera University, Nice, France
| | - Ragini Verma
- 3Department of Radiology, Diffusion and Connectomics in Precision Healthcare Research Lab, University of Pennsylvania, Philadelphia, Pennsylvania
| |
Collapse
|
2
|
Guyot J, Beucler N, Almairac F. An unexpected etiology of cerebrospinal fluid leak post-transsphenoidal surgery. Acta Neurol Belg 2024:10.1007/s13760-024-02545-6. [PMID: 38573490 DOI: 10.1007/s13760-024-02545-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Accepted: 03/27/2024] [Indexed: 04/05/2024]
Affiliation(s)
- Jean Guyot
- Neurosurgery department, Pasteur 2 Hospital, University Hospital of Nice, 30 Avenue de La Voie Romaine, 06000, Nice, France.
| | - Nathan Beucler
- Neurosurgery department, Sainte-Anne Military Teaching Hospital, Toulon, France
| | - Fabien Almairac
- Neurosurgery department, Pasteur 2 Hospital, University Hospital of Nice, 30 Avenue de La Voie Romaine, 06000, Nice, France
- UR2CA PIN, Université Côte d'Azur, Nice, France
| |
Collapse
|
3
|
Turchi L, Sakakini N, Saviane G, Polo B, Saurty-Seerunghen MS, Gabut M, Gouillou CA, Guerlais V, Pasquier C, Vignais ML, Almairac F, Chneiweiss H, Junier MP, Burel-Vandenbos F, Virolle T. CELF2 Sustains a Proliferating/OLIG2+ Glioblastoma Cell Phenotype via the Epigenetic Repression of SOX3. Cancers (Basel) 2023; 15:5038. [PMID: 37894405 PMCID: PMC10605641 DOI: 10.3390/cancers15205038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 07/23/2023] [Accepted: 08/10/2023] [Indexed: 10/29/2023] Open
Abstract
Glioblastomas (GBs) are incurable brain tumors. The persistence of aggressive stem-like tumor cells after cytotoxic treatments compromises therapeutic efficacy, leading to GBM recurrence. Forcing the GBM cells to irreversibly abandon their aggressive stem-like phenotype may offer an alternative to conventional cytotoxic treatments. Here, we show that the RNA binding protein CELF2 is strongly expressed in mitotic and OLIG2-positive GBM cells, while it is downregulated in differentiated and non-mitotic cells by miR-199a-3p, exemplifying GBM intra-tumor heterogeneity. Using patient-derived cells and human GBM samples, we demonstrate that CELF2 plays a key role in maintaining the proliferative/OLIG2 cell phenotype with clonal and tumorigenic properties. Indeed, we show that CELF2 deficiency in patient-derived GSCs drastically reduced tumor growth in the brains of nude mice. We further show that CELF2 promotes TRIM28 and G9a expression, which drive a H3K9me3 epigenetic profile responsible for the silencing of the SOX3 gene. Thus, CELF2, which is positively correlated with OLIG2 and Ki67 expression in human GBM samples, is inversely correlated with SOX3 and miR-199a-3p. Accordingly, the invalidation of SOX3 in CELF2-deficient patient-derived cells rescued proliferation and OLIG2 expression. Finally, patients expressing SOX3 above the median level of expression tend to have a longer life expectancy. CELF2 is therefore a crucial target for the malignant potential of GBM and warrants attention when developing novel anticancer strategies.
Collapse
Affiliation(s)
- Laurent Turchi
- CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France; (L.T.); (N.S.); (G.S.); (B.P.); (F.A.); (F.B.-V.)
- DRCI, CHU de Nice, 06107 Nice, France
| | - Nathalie Sakakini
- CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France; (L.T.); (N.S.); (G.S.); (B.P.); (F.A.); (F.B.-V.)
| | - Gaelle Saviane
- CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France; (L.T.); (N.S.); (G.S.); (B.P.); (F.A.); (F.B.-V.)
| | - Béatrice Polo
- CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France; (L.T.); (N.S.); (G.S.); (B.P.); (F.A.); (F.B.-V.)
| | - Mirca Saras Saurty-Seerunghen
- CNRS UMR8246, INSERM U1130, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Sorbonne Université, 75252 Paris, France; (M.S.S.-S.); (H.C.); (M.-P.J.)
| | - Mathieu Gabut
- Stemness in Gliomas Laboratory, Cancer Initiation and Tumoral Cell Identity (CITI) Department, INSERM 1052, CNRS 5286, Centre Léon Bérard, 69008 Lyon, France;
- Cancer Research Center of Lyon 1, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France
| | | | - Vincent Guerlais
- CNRS, I3S, Université Côte d’Azur, 06560 Valbonne, France; (V.G.); (C.P.)
| | - Claude Pasquier
- CNRS, I3S, Université Côte d’Azur, 06560 Valbonne, France; (V.G.); (C.P.)
| | - Marie Luce Vignais
- CNRS, INSERM, Institut de Génomique Fonctionnelle, IGF, Université de Montpellier, 34090 Montpellier, France;
| | - Fabien Almairac
- CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France; (L.T.); (N.S.); (G.S.); (B.P.); (F.A.); (F.B.-V.)
- Service de Neurochirurgie, Hôpital Pasteur, CHU de Nice, 06107 Nice, France
| | - Hervé Chneiweiss
- CNRS UMR8246, INSERM U1130, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Sorbonne Université, 75252 Paris, France; (M.S.S.-S.); (H.C.); (M.-P.J.)
| | - Marie-Pierre Junier
- CNRS UMR8246, INSERM U1130, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Sorbonne Université, 75252 Paris, France; (M.S.S.-S.); (H.C.); (M.-P.J.)
| | - Fanny Burel-Vandenbos
- CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France; (L.T.); (N.S.); (G.S.); (B.P.); (F.A.); (F.B.-V.)
- Service d’Anatomopathologie, Hôpital Pasteur, CHU de Nice, 06107 Nice, France
| | - Thierry Virolle
- CNRS, INSERM, Institut de Biologie Valrose, Team INSERM “Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity”, Université Côte D’Azur, 06107 Nice, France; (L.T.); (N.S.); (G.S.); (B.P.); (F.A.); (F.B.-V.)
| |
Collapse
|
4
|
Darcourt J, Chardin D, Bourg V, Gal J, Schiappa R, Blonski M, Koulibaly PM, Almairac F, Mondot L, Le Jeune F, Collombier L, Kas A, Taillandier L, Verger A. Added value of [ 18F]FDOPA PET to the management of high-grade glioma patients after their initial treatment: a prospective multicentre study. Eur J Nucl Med Mol Imaging 2023; 50:2727-2735. [PMID: 37086272 DOI: 10.1007/s00259-023-06225-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 04/04/2023] [Indexed: 04/23/2023]
Abstract
BACKGROUND Diagnostic value of 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine ([18F]FDOPA) PET in patients with suspected recurrent gliomas is recognised. We conducted a multicentre prospective study to assess its added value in the practical management of patients suspected of recurrence of high grade gliomas (HGG). METHODS Patients with a proven HGG (WHO grade III and IV) were referred to the multidisciplinary neuro-oncology board (MNOB) during their follow-up after initial standard of care treatment and when MRI findings were not fully conclusive. Each case was discussed in 2 steps. For step 1, a diagnosis and a management proposal were made only based on the clinical and the MRI data. For step 2, the same process was repeated taking the [18F]FDOPA PET results into consideration. A level of confidence for the decisions was assigned to each step. Changes in diagnosis and management induced by [18F]FDOPA PET information were measured. When unchanged, the difference in the confidence of the decisions were assessed. The diagnostic performances of each step were measured. RESULTS 107 patients underwent a total of 138 MNOB assessments. The proposed diagnosis changed between step 1 and step 2 in 37 cases (26.8%) and the proposed management changed in 31 cases (22.5%). When the management did not change, the confidence in the MNOB final decision was increased in 87 cases (81.3%). Step 1 had a sensitivity, specificity and accuracy of 83%, 58% and 66% and step 2, 86%, 64% and 71% respectively. CONCLUSION [18F]FDOPA PET adds significant information for the follow-up of HGG patients in clinical practice. When MRI findings are not straightforward, it can change the management for more than 20% of the patients and increases the confidence level of the multidisciplinary board decisions.
Collapse
Affiliation(s)
- Jacques Darcourt
- Department of Nuclear Medicine, Centre Antoine Lacassagne and UMR 4320 CEA-UCA, Université Côte d'Azur, Nice, France.
| | - David Chardin
- Department of Nuclear Medicine, Centre Antoine Lacassagne and UMR 4320 CEA-UCA, Université Côte d'Azur, Nice, France
| | - Véronique Bourg
- Department of Neurology, CHU, Nice, Université Cote d'Azur, Nice, France
| | - Jocelyn Gal
- Epidemiology and Biostatistics Department, Centre Antoine Lacassagne and Université Côte d'Azur, Nice, France
| | - Renaud Schiappa
- Epidemiology and Biostatistics Department, Centre Antoine Lacassagne and Université Côte d'Azur, Nice, France
| | - Marie Blonski
- Department of Neuro-Oncology, CHU, Nancy and CNRS, UMR 7039, Université de Lorraine, Nancy, France
| | - Pierre-Malick Koulibaly
- Department of Nuclear Medicine, Centre Antoine Lacassagne and UMR 4320 CEA-UCA, Université Côte d'Azur, Nice, France
| | - Fabien Almairac
- Department of Neurosurgery, CHU Nice and UR2CA Team PIN, Université Côte d'Azur, Nice, France
| | - Lydiane Mondot
- Department of Radiology, CHU Nice, Université Côte d'Azur, Nice, France
| | - Florence Le Jeune
- Department of Nuclear Medicine, Centre Eugène Marquis, Rennes and LTSI INSERM 1099, Université de Rennes 1, Rennes, France
| | - Laurent Collombier
- Department of Nuclear Medicine, CHU Nîmes, Université de Montpellier, Nîmes, France
| | - Aurélie Kas
- Department of Nuclear Medicine, AP-HP Hôpitaux Universitaires Pitié-Salpétrière Charles Foix and LIB INSERM U1146, Sorbonne University, Paris, France
| | - Luc Taillandier
- Department of Neuro-Oncology, CHU, Nancy and CNRS, UMR 7039, Université de Lorraine, Nancy, France
| | - Antoine Verger
- Department of Nuclear Medicine & Nancyclotep Imaging Platform, CHU Nancy and IADI INSERM UMR 1254, Université de Lorraine, Nancy, France
| |
Collapse
|
5
|
Golkar E, Parker D, Brem S, Almairac F, Verma R. CrOssing fiber Modeling in the Peritumoral Area using dMRI (COMPARI). bioRxiv 2023:2023.05.07.539770. [PMID: 37215003 PMCID: PMC10197585 DOI: 10.1101/2023.05.07.539770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Visualization of fiber tracts around the tumor is critical for neurosurgical planning and preservation of crucial structural connectivity during tumor resection. Biophysical modeling approaches estimate fiber tract orientations from differential water diffusivity information of diffusion MRI. However, the presence of edema and tumor infiltration presents a challenge to visualize crossing fiber tracts in the peritumoral region. Previous approaches proposed free water modeling to compensate for the effect of water diffusivity in edema, but those methods were limited in estimating complex crossing fiber tracts. We propose a new cascaded multi-compartment model to estimate tissue microstructure in the presence of edema and pathological contaminants in the area surrounding brain tumors. In our model (COMPARI), the isotropic components of diffusion signal, including free water and hindered water, were eliminated, and the fiber orientation distribution (FOD) of the remaining signal was estimated. In simulated data, COMPARI accurately recovered fiber orientations in the presence of extracellular water. In a dataset of 23 patients with highly edematous brain tumors, the amplitudes of FOD and anisotropic index distribution within the peritumoral region were higher with COMPARI than with a recently proposed multi-compartment constrained deconvolution model. In a selected patient with metastatic brain tumor, we demonstrated COMPARI's ability to effectively model and eliminate water from the peritumoral region. The white matter bundles reconstructed with our model were qualitatively improved compared to those of other models, and allowed the identification of crossing fibers. In conclusion, the removal of isotropic components as proposed with COMPARI improved the bio-physical modeling of dMRI in edema, thus providing information on crossing fibers, thereby enabling improved tractography in a highly edematous brain tumor. This model may improve surgical planning tools to help achieve maximal safe resection of brain tumors.
Collapse
Affiliation(s)
- Ehsan Golkar
- DiCIPHR (Diffusion and Connectomics in Precision Healthcare Research) Lab, Perelman School of Medicine,University of Pennsylvania, Philadelphia, PA, USA
| | - Drew Parker
- DiCIPHR (Diffusion and Connectomics in Precision Healthcare Research) Lab, Perelman School of Medicine,University of Pennsylvania, Philadelphia, PA, USA
| | - Steven Brem
- Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania,Philadelphia, PA
| | - Fabien Almairac
- Neurosurgery department, Pasteur 2 Hospital, University Hospital of Nice, France
- UR2CA PIN, Université Côte d’Azur, France
| | - Ragini Verma
- DiCIPHR (Diffusion and Connectomics in Precision Healthcare Research) Lab, Perelman School of Medicine,University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
6
|
Almairac F, Parker D, Mondot L, Isan P, Onno M, Papadopoulo T, Filipiak P, Fontaine D, Verma R. Free-water correction DTI-based tractography in brain tumor surgery: assessment with functional and electrophysiological mapping of the white matter. Acta Neurochir (Wien) 2023; 165:1675-1681. [PMID: 37129683 DOI: 10.1007/s00701-023-05608-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Accepted: 04/20/2023] [Indexed: 05/03/2023]
Abstract
Peritumoral edema prevents fiber tracking from diffusion tensor imaging (DTI). A free-water correction may overcome this drawback, as illustrated in the case of a patient undergoing awake surgery for brain metastasis. The anatomical plausibility and accuracy of tractography with and without free-water correction were assessed with functional mapping and axono-cortical evoked-potentials (ACEPs) as reference methods. The results suggest a potential synergy between corrected DTI-based tractography and ACEPs to reliably identify and preserve white matter tracts during brain tumor surgery.
Collapse
Affiliation(s)
- Fabien Almairac
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 06000, Nice, France.
- UR2CA PIN, Université Côte d'Azur, Nice, France.
| | - Drew Parker
- Diffusion and Connectomics in Precision Healthcare Research Lab, Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Lydiane Mondot
- Neuroradiology department, Pasteur 2 Hospital, University Hospital of Nice, 06000, Nice, France
- UR2CA URRIS, Université Côte d'Azur, Nice, France
| | - Petru Isan
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 06000, Nice, France
- UR2CA PIN, Université Côte d'Azur, Nice, France
| | - Marie Onno
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 06000, Nice, France
| | | | | | - Denys Fontaine
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 06000, Nice, France
- UR2CA PIN, Université Côte d'Azur, Nice, France
| | - Ragini Verma
- Diffusion and Connectomics in Precision Healthcare Research Lab, Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| |
Collapse
|
7
|
Martel A, Nahon-Estève S, Almairac F, Baillif S. Ultrasonic orbital tumor debulking… with a phaco tip! Does it work? J Fr Ophtalmol 2023; 46:430-432. [PMID: 36863902 DOI: 10.1016/j.jfo.2022.08.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2022] [Revised: 08/15/2022] [Accepted: 08/26/2022] [Indexed: 03/04/2023]
Affiliation(s)
- A Martel
- Service d'ophtalmologie, CHU de Nice, université Côte d'Azur, hôpital Pasteur, 30, voie Romaine, 06000 Nice, France; Laboratoire de pathologie clinique et expérimentale (LPCE), CHU de Nice, université Côte d'Azur, hôpital Pasteur, 30, voie Romaine, 06000 Nice, France.
| | - S Nahon-Estève
- Service d'ophtalmologie, CHU de Nice, université Côte d'Azur, hôpital Pasteur, 30, voie Romaine, 06000 Nice, France; Centre méditerranéen de médecine moléculaire (C3M), équipe 1, Inserm U1065, Nice, France
| | - F Almairac
- Service de neurochirurgie, CHU de Nice, université Côte d'Azur, hôpital Pasteur, 30, voie Romaine, 06000 Nice, France
| | - S Baillif
- Service d'ophtalmologie, CHU de Nice, université Côte d'Azur, hôpital Pasteur, 30, voie Romaine, 06000 Nice, France
| |
Collapse
|
8
|
Almairac F, Isan P, Onno M, Papadopoulo T, Mondot L, Chanalet S, Fernandez C, Clerc M, Deriche R, Fontaine D, Filipiak P. Identifying subcortical connectivity during brain tumor surgery: a multimodal study. Brain Struct Funct 2023; 228:815-830. [PMID: 36840759 DOI: 10.1007/s00429-023-02623-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Accepted: 02/16/2023] [Indexed: 02/26/2023]
Abstract
Bipolar direct electrical stimulation (DES) of an awake patient is the reference technique for identifying brain structures to achieve maximal safe tumor resection. Unfortunately, DES cannot be performed in all cases. Alternative surgical tools are, therefore, needed to aid identification of subcortical connectivity during brain tumor removal. In this pilot study, we sought to (i) evaluate the combined use of evoked potential (EP) and tractography for identification of white matter (WM) tracts under the functional control of DES, and (ii) provide clues to the electrophysiological effects of bipolar stimulation on neural pathways. We included 12 patients (mean age of 38.4 years) who had had a dMRI-based tractography and a functional brain mapping under awake craniotomy for brain tumor removal. Electrophysiological recordings of subcortical evoked potentials (SCEPs) were acquired during bipolar low frequency (2 Hz) stimulation of the WM functional sites identified during brain mapping. SCEPs were successfully triggered in 11 out of 12 patients. The median length of the stimulated fibers was 43.24 ± 19.55 mm, belonging to tracts of median lengths of 89.84 ± 24.65 mm. The electrophysiological (delay, amplitude, and speed of propagation) and structural (number and lengths of streamlines, and mean fractional anisotropy) measures were correlated. In our experimental conditions, SCEPs were essentially limited to a subpart of the bundles, suggesting a selectivity of action of the DES on the brain networks. Correlations between functional, structural, and electrophysiological measures portend the combined use of EPs and tractography as a potential intraoperative tool to achieve maximum safe resection in brain tumor surgery.
Collapse
Affiliation(s)
- Fabien Almairac
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 30 Avenue de La Voie Romaine, 06000, Nice, France.
- UR2CA PIN, Université Côte d'Azur, Nice, France.
| | - Petru Isan
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 30 Avenue de La Voie Romaine, 06000, Nice, France
- UR2CA PIN, Université Côte d'Azur, Nice, France
- Athena Team, Centre Inria d'Université Côte d'Azur, Sophia Antipolis, France
| | - Marie Onno
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 30 Avenue de La Voie Romaine, 06000, Nice, France
| | | | - Lydiane Mondot
- Neuroradiology Department, Pasteur 2 Hospital, University Hospital of Nice, Nice, France
- UR2CA URRIS, Université Côte d'Azur, Nice, France
| | - Stéphane Chanalet
- Neuroradiology Department, Pasteur 2 Hospital, University Hospital of Nice, Nice, France
| | - Charlotte Fernandez
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 30 Avenue de La Voie Romaine, 06000, Nice, France
| | - Maureen Clerc
- Athena Team, Centre Inria d'Université Côte d'Azur, Sophia Antipolis, France
| | - Rachid Deriche
- Athena Team, Centre Inria d'Université Côte d'Azur, Sophia Antipolis, France
| | - Denys Fontaine
- Neurosurgery Department, Pasteur 2 Hospital, University Hospital of Nice, 30 Avenue de La Voie Romaine, 06000, Nice, France
- UR2CA PIN, Université Côte d'Azur, Nice, France
| | | |
Collapse
|
9
|
Almairac F, Leplus A, Mondot L, Fontaine D. A New Noninvasive Frameless Registration System for Stereotactic Cranial Biopsy: A Technical Note. Oper Neurosurg (Hagerstown) 2023; 24:64-67. [PMID: 36227183 DOI: 10.1227/ons.0000000000000426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 07/16/2022] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND Although frame-based stereotactic biopsy is still considered the gold standard for brain biopsies, frameless robot-assisted stereotactic systems are now able to provide an equal level of safety and accuracy. However, both systems suffer from a lack of efficiency of the operative workflow. OBJECTIVE To describe the technique of a new frameless and noninvasive registration tool Neurolocate (Renishaw). This tool, combined with an intraoperative cone-beam computed tomography imaging system like O-ARM (Medtronic), might facilitate the achievement and workflow of robot-assisted stereotactic intracranial biopsies. METHODS Neurolocate is a 3-dimensional fiducial tool fixed directly on the Neuromate (Renishaw) robot arm. It consists of 5 radio-opaque spherical fiducials, whose geometry is constant. This tool made it possible to carry out the coregistration then the biopsy in the same operating time, following a five-step procedure described here. We retrospectively extracted selected preliminary results from our initial experience. RESULTS Over 1 year, 23 consecutive adult patients were biopsied with Neurolocate in our center. The mean overall operative time, from patient's installation to skin closure, was 97 minutes ± 27 (SD). The entire procedure took place in a single location unit (operating room), which facilitated workflow and surgical planning. No invasive gesture was performed outside of the operating time. CONCLUSION Neurolocate is a new frameless and noninvasive registration tool that could improve workflow and flexibility for operating room management and surgical planning. It may also increase the comfort of patients undergoing robot-assisted intracranial stereotactic biopsies. The accuracy and safety profile should be addressed in specific studies.
Collapse
Affiliation(s)
- Fabien Almairac
- Neurosurgery Department, Hôpital Pasteur 2, CHU de Nice, Nice, France.,UR2CA PIN, Université Côte d'Azur, Nice, France
| | - Aurélie Leplus
- Neurosurgery Department, Hôpital Pasteur 2, CHU de Nice, Nice, France.,UR2CA PIN, Université Côte d'Azur, Nice, France
| | - Lydiane Mondot
- Neuroradiology Department, Hôpital Pasteur 2, CHU de Nice, Nice, France.,UR2CA URRIS, Université Côte d'Azur, Nice, France
| | - Denys Fontaine
- Neurosurgery Department, Hôpital Pasteur 2, CHU de Nice, Nice, France.,UR2CA PIN, Université Côte d'Azur, Nice, France
| |
Collapse
|
10
|
Saurty-Seerunghen MS, Daubon T, Bellenger L, Delaunay V, Castro G, Guyon J, Rezk A, Fabrega S, Idbaih A, Almairac F, Burel-Vandenbos F, Turchi L, Duplus E, Virolle T, Peyrin JM, Antoniewski C, Chneiweiss H, El-Habr EA, Junier MP. Glioblastoma cell motility depends on enhanced oxidative stress coupled with mobilization of a sulfurtransferase. Cell Death Dis 2022. [PMID: 36310164 DOI: 10.1038/s41419-022-05358-8.pmid:36310164;pmcid:pmc9618559] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
Abstract
Cell motility is critical for tumor malignancy. Metabolism being an obligatory step in shaping cell behavior, we looked for metabolic weaknesses shared by motile cells across the diverse genetic contexts of patients' glioblastoma. Computational analyses of single-cell transcriptomes from thirty patients' tumors isolated cells with high motile potential and highlighted their metabolic specificities. These cells were characterized by enhanced mitochondrial load and oxidative stress coupled with mobilization of the cysteine metabolism enzyme 3-Mercaptopyruvate sulfurtransferase (MPST). Functional assays with patients' tumor-derived cells and -tissue organoids, and genetic and pharmacological manipulations confirmed that the cells depend on enhanced ROS production and MPST activity for their motility. MPST action involved protection of protein cysteine residues from damaging hyperoxidation. Its knockdown translated in reduced tumor burden, and a robust increase in mice survival. Starting from cell-by-cell analyses of the patients' tumors, our work unravels metabolic dependencies of cell malignancy maintained across heterogeneous genomic landscapes.
Collapse
Affiliation(s)
- Mirca S Saurty-Seerunghen
- CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Thomas Daubon
- CNRS UMR5095, Inserm U1029, Université de Bordeaux, Institut de Biochimie et Génétique Cellulaires, Team Bioenergetics and dynamics of mitochondria, Bordeaux, France
| | - Léa Bellenger
- ARTbio Bioinformatics Analysis Facility, Sorbonne Université, CNRS, Institut de Biologie Paris Seine, Paris, France
| | - Virgile Delaunay
- CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Gloria Castro
- CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Joris Guyon
- Inserm U1312, Université de Bordeaux, Pessac, France
| | - Ahmed Rezk
- CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Sylvie Fabrega
- Plateforme Vecteurs Viraux et Transfert de Gènes, Université Paris Descartes-Structure Fédérative de Recherche Necker, CNRS UMS3633, Inserm US24, Paris, France
| | - Ahmed Idbaih
- CNRS UMR 7225, Inserm U1127, Sorbonne Université, Institut du Cerveau et de la Moelle épinière, Paris, France
| | - Fabien Almairac
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity, Nice, France
- Service de Neurochirurgie, Hôpital Pasteur, CHU de Nice, Nice, 06107, France
| | - Fanny Burel-Vandenbos
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity, Nice, France
- Service d'anatomopathologie, Hôpital Pasteur, CHU de Nice, Nice, 06107, France
| | - Laurent Turchi
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity, Nice, France
- DRCI, CHU de Nice, Nice, 06107, France
| | - Eric Duplus
- CNRS UMR8256, INSERM ERL1164, Sorbonne Université, Biological adaptation and aging-IBPS Laboratory, Team Integrated cellular aging and inflammation, Paris, France
| | - Thierry Virolle
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity, Nice, France
| | - Jean-Michel Peyrin
- CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Axonal degeneration and regeneration, Paris, France
| | - Christophe Antoniewski
- ARTbio Bioinformatics Analysis Facility, Sorbonne Université, CNRS, Institut de Biologie Paris Seine, Paris, France
| | - Hervé Chneiweiss
- CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Elias A El-Habr
- CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France.
| | - Marie-Pierre Junier
- CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France.
| |
Collapse
|
11
|
Saurty-Seerunghen MS, Daubon T, Bellenger L, Delaunay V, Castro G, Guyon J, Rezk A, Fabrega S, Idbaih A, Almairac F, Burel-Vandenbos F, Turchi L, Duplus E, Virolle T, Peyrin JM, Antoniewski C, Chneiweiss H, El-Habr EA, Junier MP. Glioblastoma cell motility depends on enhanced oxidative stress coupled with mobilization of a sulfurtransferase. Cell Death Dis 2022; 13:913. [PMID: 36310164 PMCID: PMC9618559 DOI: 10.1038/s41419-022-05358-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 10/17/2022] [Accepted: 10/19/2022] [Indexed: 01/23/2023]
Abstract
Cell motility is critical for tumor malignancy. Metabolism being an obligatory step in shaping cell behavior, we looked for metabolic weaknesses shared by motile cells across the diverse genetic contexts of patients' glioblastoma. Computational analyses of single-cell transcriptomes from thirty patients' tumors isolated cells with high motile potential and highlighted their metabolic specificities. These cells were characterized by enhanced mitochondrial load and oxidative stress coupled with mobilization of the cysteine metabolism enzyme 3-Mercaptopyruvate sulfurtransferase (MPST). Functional assays with patients' tumor-derived cells and -tissue organoids, and genetic and pharmacological manipulations confirmed that the cells depend on enhanced ROS production and MPST activity for their motility. MPST action involved protection of protein cysteine residues from damaging hyperoxidation. Its knockdown translated in reduced tumor burden, and a robust increase in mice survival. Starting from cell-by-cell analyses of the patients' tumors, our work unravels metabolic dependencies of cell malignancy maintained across heterogeneous genomic landscapes.
Collapse
Affiliation(s)
- Mirca S. Saurty-Seerunghen
- grid.462844.80000 0001 2308 1657CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Thomas Daubon
- grid.462122.10000 0004 1795 2841CNRS UMR5095, Inserm U1029, Université de Bordeaux, Institut de Biochimie et Génétique Cellulaires, Team Bioenergetics and dynamics of mitochondria, Bordeaux, France
| | - Léa Bellenger
- grid.503253.20000 0004 0520 7190ARTbio Bioinformatics Analysis Facility, Sorbonne Université, CNRS, Institut de Biologie Paris Seine, Paris, France
| | - Virgile Delaunay
- grid.462844.80000 0001 2308 1657CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Gloria Castro
- grid.462844.80000 0001 2308 1657CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Joris Guyon
- grid.412041.20000 0001 2106 639XInserm U1312, Université de Bordeaux, Pessac, France
| | - Ahmed Rezk
- grid.462844.80000 0001 2308 1657CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Sylvie Fabrega
- grid.508487.60000 0004 7885 7602Plateforme Vecteurs Viraux et Transfert de Gènes, Université Paris Descartes-Structure Fédérative de Recherche Necker, CNRS UMS3633, Inserm US24, Paris, France
| | - Ahmed Idbaih
- grid.425274.20000 0004 0620 5939CNRS UMR 7225, Inserm U1127, Sorbonne Université, Institut du Cerveau et de la Moelle épinière, Paris, France
| | - Fabien Almairac
- grid.461605.0Université Côte D’Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity, Nice, France ,grid.464719.90000 0004 0639 4696Service de Neurochirurgie, Hôpital Pasteur, CHU de Nice, Nice, 06107 France
| | - Fanny Burel-Vandenbos
- grid.461605.0Université Côte D’Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity, Nice, France ,grid.464719.90000 0004 0639 4696Service d’anatomopathologie, Hôpital Pasteur, CHU de Nice, Nice, 06107 France
| | - Laurent Turchi
- grid.461605.0Université Côte D’Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity, Nice, France ,grid.410528.a0000 0001 2322 4179DRCI, CHU de Nice, Nice, 06107 France
| | - Eric Duplus
- grid.462844.80000 0001 2308 1657CNRS UMR8256, INSERM ERL1164, Sorbonne Université, Biological adaptation and aging-IBPS Laboratory, Team Integrated cellular aging and inflammation, Paris, France
| | - Thierry Virolle
- grid.461605.0Université Côte D’Azur, CNRS, INSERM, Institut de Biologie Valrose, Team INSERM Cancer Stem Cell Plasticity and Functional Intra-tumor Heterogeneity, Nice, France
| | - Jean-Michel Peyrin
- grid.462844.80000 0001 2308 1657CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Axonal degeneration and regeneration, Paris, France
| | - Christophe Antoniewski
- grid.503253.20000 0004 0520 7190ARTbio Bioinformatics Analysis Facility, Sorbonne Université, CNRS, Institut de Biologie Paris Seine, Paris, France
| | - Hervé Chneiweiss
- grid.462844.80000 0001 2308 1657CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Elias A. El-Habr
- grid.462844.80000 0001 2308 1657CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| | - Marie-Pierre Junier
- grid.462844.80000 0001 2308 1657CNRS UMR8246, Inserm U1130, Sorbonne Université, Neuroscience Paris Seine-IBPS Laboratory, Team Glial Plasticity and NeuroOncology, Paris, France
| |
Collapse
|
12
|
Joly H, Cochet S, Almairac F, Mondot L, Lebrun-Frenay C, Fontaine D. Suivi longitudinal de la cognition dans les gliomes de bas grade. Rev Neurol (Paris) 2022. [DOI: 10.1016/j.neurol.2022.02.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Isan P, Mondot L, Casolla B, Fontaine D, Almairac F. Post-traumatic cerebral venous sinus thrombosis associated with epidural hematoma: A challenging clinical situation. Neurochirurgie 2022; 68:e40-e43. [DOI: 10.1016/j.neuchi.2021.12.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2021] [Revised: 12/10/2021] [Accepted: 12/28/2021] [Indexed: 11/24/2022]
|
14
|
Sumodhee S, Atallah V, Kinj R, Doyen J, L'Homel B, Gillon P, Paquis P, Almairac F, Hieronimus S, Schiappa R, Sadoul JL, Sumodhee D, Pontikos N, Richier Q, Hannoun-Levi JM, Scouarnec C, Chevalier N, Bondiau PY. Fractionated Stereotactic Radiation Therapy for Pituitary Adenomas: An alternative escalating protocol of hypofractionated stereotactic radiotherapy delivering 35Gy in 5 fractions. Cancer Radiother 2021; 26:557-562. [PMID: 34711487 DOI: 10.1016/j.canrad.2021.08.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2021] [Revised: 08/03/2021] [Accepted: 08/07/2021] [Indexed: 10/20/2022]
Abstract
PURPOSE Evaluate efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) for patients treated for pituitary adenoma (PA) with an alternative HSRT escalating protocol delivering 35Gy in 5 fractions. MATERIAL AND METHODS From June 2007 to March 2017, 29 patients with pituitary adenoma were treated in Antoine Lacassagne Cancer Centre with an alternative HSRT protocol. Prescribed dose was 35Gy in 5 fractions of 7Gy. Radiographic responses were assessed by annual MRI. Hormone blood samples were evaluated each year after HSRT. RESULTS A total of 29 patients aged between 23 and 86 years (median 54 years) were included. Twelve patients received HSRT for recurrent cases and 12 received postoperative adjuvant HSRT, 5 patients did not have surgery. After a median follow-up period of 47 months local control rate was 96%. One patient presented an out-field tumor regrowth 73 months after HSRT. The majority of PA were endocrine-active (18 patients, 62%). After HSRT, 8 patients (44%) presented complete response on initial secretion, 4 patients (23%) presented partial response on initial secretion. Four patients (14%) presented grade 2 or more acute radiation toxicities. One grade 4 visual disorder was observed for one patient. CONCLUSIONS HSRT delivering 35Gy in 5 fractions represents a feasible treatment and shows promising results to reduce hormonal overproduction and to improve local control in PA.
Collapse
Affiliation(s)
- S Sumodhee
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France.
| | - V Atallah
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - R Kinj
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - J Doyen
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - B L'Homel
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - P Gillon
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - P Paquis
- Department of Neurosurgery, Centre Hospitalier Universitaire de Nice, Nice, France
| | - F Almairac
- Department of Neurosurgery, Centre Hospitalier Universitaire de Nice, Nice, France
| | - S Hieronimus
- Department of Endocrinology, Centre Hospitalier Universitaire de Nice, Nice, France
| | - R Schiappa
- Department of Biostatistics, Centre Antoine-Lacassagne, Nice, France
| | - J-L Sadoul
- Department of Endocrinology, Centre Hospitalier Universitaire de Nice, Nice, France
| | - D Sumodhee
- Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College, London, UK
| | - N Pontikos
- UCL Institute of Ophthalmology, University College London, London, UK
| | - Q Richier
- Department of Internal Medicine, CHU de La Réunion, 97400 Saint Denis, France
| | - J-M Hannoun-Levi
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - C Scouarnec
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| | - N Chevalier
- Department of Neurosurgery, Centre Hospitalier Universitaire de Nice, Nice, France
| | - P-Y Bondiau
- Department of Radiation Oncology, Centre Antoine-Lacassagne, University Côte d'Azur, 33, avenue de Valombrose, 06189 Nice, France
| |
Collapse
|
15
|
Martel A, Baillif S, Thomas P, Almairac F, Galatoire O, Hamedani M, Fontaine D, Lanteri‐Minet M. Phantom eye pain: a multicentric study in 100 patients. Acta Ophthalmol 2021; 99:e753-e760. [PMID: 33124153 DOI: 10.1111/aos.14657] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 09/25/2020] [Accepted: 09/29/2020] [Indexed: 12/28/2022]
Abstract
PURPOSE Phantom eye syndrome (PES) is an underestimated complication of eye amputation (EA) characterized by phantom eye pain (PEP), phantom visions and/or phantom sensations. The aim of this study was to assess PEP prevalence, features, risk factors, social and psychological consequences and associated quality of life. METHODS A questionnaire study was conducted in three oculoplastic departments between April 2016 and July 2017. Patients >18 years who had undergone EA ≥3 months earlier were included and asked to complete a prestamped questionnaire. Patient's characteristics, preoperative, surgical and postoperative data were collected. RESULTS Of the 185 questionnaires given, 115 (62%) were returned for analysis. Hundred patients with a mean age of 65.1 years (29-92; SD = 13.0) were included. Eye amputation (EA) indications were uveal melanoma (n = 24, 24%), trauma (n = 20, 20%), retinal detachment (n = 20, 20%), glaucoma (n = 14, 14%) and endophthalmitis (n = 12, 12%). Forty-seven (47%), 30 (30%) and 38 (38%) patients experienced PEP, phantom visions and phantom sensations, respectively. Anxiety and depression [Hospital Anxiety Depression scale (HADS) score ≥8 for both] were diagnosed in 34 (34%) and 42 (42%) patients, respectively. The mean EQ-5D-3L and EQ-5D visual analogue scale scores were 0.8 (0.06-1; SD = 0.2) and 68 (0-100; SD = 22), respectively. Preoperative eye pain (p = 0.031), glaucoma (p = 0.027), postoperative anxiety with HADS score ≥8 (p = 0.012) and ≥11 (p = 0.014), aesthetic discomfort (p = 0.002) and EQ-5D-3L score <0.8 (p < 0.001) were significantly associated with PEP in the univariate analysis. In the multivariate analysis, only anxiety (HADS score ≥8) was significantly associated with PEP (p = 0.009). CONCLUSION Phantom eye pain (PEP) is a common complication of EA strongly associated with postoperative anxiety.
Collapse
Affiliation(s)
- Arnaud Martel
- Ophthalmology Department University Hospital of Nice Nice France
| | | | - Pierre Thomas
- Neurology Department University Hospital of Nice Nice France
| | - Fabien Almairac
- Neurosurgery Department University Hospital of NiceFédération Hospitalo‐Universitaire InovPainCote d'Azur University Nice France
| | | | - Mehrad Hamedani
- Oculoplastic Department Jules Gonin Eye Hospital Lausanne Switzerland
| | - Denys Fontaine
- Neurosurgery Department University Hospital of NiceFédération Hospitalo‐Universitaire InovPainCote d'Azur University Nice France
| | - Michel Lanteri‐Minet
- Pain Evaluation and Management Department University Hospital of NiceFédération Hospitalo‐Universitaire InovPainCote d'Azur University Nice France
| |
Collapse
|
16
|
Denis E, Orlhac F, Gal J, Schiappa R, Humbert O, Bourg V, Almairac F, Fauchon F, Mondot L. Faisabilité d’une étude radiomique en routine clinique dans une cohorte de patients traités pour un glioblastome présentant une nouvelle lésion rehaussée au cours du suivi IRM. J Neuroradiol 2021. [DOI: 10.1016/j.neurad.2021.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Martel A, Baillif S, Thomas P, Almairac F, Galatoire O, Hamedani M, Fontaine D, Lanteri-Minet M. Phantom vision after eye removal: prevalence, features and related risk factors. Br J Ophthalmol 2021; 106:1603-1609. [PMID: 33980507 DOI: 10.1136/bjophthalmol-2021-319091] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Revised: 04/08/2021] [Accepted: 04/23/2021] [Indexed: 12/14/2022]
Abstract
AIM Phantom eye syndrome is a poorly understood and underestimated complication of eye removal (ER). Seeing with the amputated eye, referred to as phantom vision (PV), is undoubtedly the most intriguing and confusing complication experienced by anophthalmic patients. The aim of the study was to assess PV prevalence, clinical features and risk factors after ER. METHODS A multicentric questionnaire-based study was conducted between April 2016 and July 2017. Patients >18 years who underwent ER >3 months ago had a socket examination before inclusion. Data recorded included patients' demographics, and preoperative, surgical and postoperative features. RESULTS One hundred patients (53 men) with a mean age of 65.1 years (29-92; SD=13.0) were included. ER indications were: uveal melanoma (n=24, 24%), trauma (n=20, 20%), retinal detachment (n=20, 20%), glaucoma (n=14, 14%) and endophthalmitis (n=12, 12%). Thirty (30%) patients experienced PV. Elementary and complex visual hallucinations were experienced by 80% and 20% of patients, respectively. PV usually appeared within the first postoperative month and tended to decrease over time. Risk factors for PV were the preoperative use of proton beam therapy (p=0.006), uveal melanoma (p=0.014), enucleation (p=0.015), anxiety with a Hospital and Anxiety Depression (HAD) score ≥8 (p=0.042), depression with a HAD score ≥8 (p=0.030), phantom eye pain (p=0.044) and phantom eye sensations (p=0.002). CONCLUSION PV was reported by one-third of our patients. Despite being widely misunderstood, ophthalmologists and neurologists should be aware of this complication to adequately reassure patients.
Collapse
Affiliation(s)
- Arnaud Martel
- Ophthalmology, University Hospital Centre Nice, Nice, Provence-Alpes-Côte d'Azur, France
| | - Stephanie Baillif
- Ophthalmology, University Hospital Centre Nice, Nice, Provence-Alpes-Côte d'Azur, France
| | - Pierre Thomas
- Neurology, University Hospital Centre Nice, Nice, Provence-Alpes-Côte d'Azur, France
| | - Fabien Almairac
- Neurosurgery, University Hospital Centre Nice, Nice, Provence-Alpes-Côte d'Azur, France
| | | | | | - Denys Fontaine
- Neurosurgery, University Hospital Centre Nice, Nice, Provence-Alpes-Côte d'Azur, France
| | - Michel Lanteri-Minet
- Pain Evaluation and Management Department, University Hospital of Nice, Fédération Hospitalo-Universitaire InovPain, Cote d'Azur University, University Hospital Centre Nice, Nice, Provence-Alpes-Côte d'Azur, France
| |
Collapse
|
18
|
Gavotto A, Feuillade V, Bresch S, Guevara N, Mondot L, Almairac F. Papilledema secondary to vestibular schwannoma: An atypical case without intracranial hypertension. Neurochirurgie 2021; 68:327-330. [PMID: 33989639 DOI: 10.1016/j.neuchi.2021.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 04/23/2021] [Accepted: 04/27/2021] [Indexed: 11/30/2022]
Abstract
In most cases, vestibular schwannomas with papilledema are associated with intracranial hypertension secondary to hydrocephalus (obstructive or communicating). We describe the atypical case of a 39-years-old man who presented with bilateral papilledema revealing a vestibular schwannoma, but without hydrocephalus and with normal intracranial pressure. Ophtalmologic signs were completely resolved after tumor removal. The pathophysiological mechanism generally described to explain bilateral papilledema in such cases is tumor-induced hyperproteinorachia. However, in the absence of hydrocephalus or intracranial hypertension, this case raises the question of the mechanisms involved in the visual impairment related to vestibular schwannoma.
Collapse
Affiliation(s)
- A Gavotto
- Service de neurochirurgie, hôpital Pasteur 2, CHU de Nice, 30, avenue de la voie romaine, 06000 Nice, France; Université Côte d'Azur, Nice, France
| | - V Feuillade
- Université Côte d'Azur, Nice, France; Service d'ophtalmologie, hôpital Pasteur 2, Nice, France
| | - S Bresch
- Université Côte d'Azur, Nice, France; Centre de ressources et de compétences Sclérose en Plaques (CRCSEP), hôpital Pasteur 2, Nice, France
| | - N Guevara
- Université Côte d'Azur, Nice, France; Service d'ORL, IUFC, Nice, France
| | - L Mondot
- Université Côte d'Azur, Nice, France; Service de radiologie, hôpital Pasteur 2, Nice, France
| | - F Almairac
- Service de neurochirurgie, hôpital Pasteur 2, CHU de Nice, 30, avenue de la voie romaine, 06000 Nice, France; Université Côte d'Azur, Nice, France.
| |
Collapse
|
19
|
Almairac F, Deverdun J, Cochereau J, Coget A, Lemaitre AL, Moritz-Gasser S, Duffau H, Herbet G. Homotopic redistribution of functional connectivity in insula-centered diffuse low-grade glioma. Neuroimage Clin 2021; 29:102571. [PMID: 33508623 PMCID: PMC7840474 DOI: 10.1016/j.nicl.2021.102571] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2020] [Revised: 01/12/2021] [Accepted: 01/13/2021] [Indexed: 12/16/2022]
Abstract
OBJECTIVE In the event of neural injury, the homologous contralateral brain areas may play a compensatory role to avoid or limit the functional loss. However, this dynamic strategy of functional redistribution is not clearly established, especially in the pathophysiological context of diffuse low-grade glioma. Our aim here was to assess the extent to which unilateral tumor infiltration of the insula dynamically modulates the functional connectivity of the contralesional one. METHODS Using resting-state functional connectivity MRI, a seed-to-ROI approach was employed in 52 insula-centered glioma patients (n = 30 left and 22 right) compared with 19 age-matched healthy controls. RESULTS Unsurprisingly, a significant decrease of the inter-insular connectivity was observed in both patient groups. More importantly, the analyses revealed a significant increase of the contralesional insular connectivity towards both cerebral hemispheres, especially in cortical areas forming the visual and the sensorimotor networks. This functional redistribution was not identified when the analyses were performed on three control regions for which the homologous area was not impaired by the tumor. This overall pattern of results indicates that massive infiltration of the insular cortex causes a significant redeployment of the contralesional functional connectivity. CONCLUSION This general finding suggests that the undamaged insula plays a role in the functional compensation usually observed in this patient population, and thus provides compelling support for the concept of homotopic functional plasticity in brain-damaged patients.
Collapse
Affiliation(s)
- Fabien Almairac
- Department of Neurosurgery, Pasteur 2 Hospital, Nice University Medical Center, Nice, France; Université Côte d'Azur, Nice, France
| | - Jeremy Deverdun
- I2FH, Institut d'Imagerie Fonctionnelle Humaine, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France; Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
| | - Jérôme Cochereau
- Department of Neurosurgery, La Miletrie Hospital, Poitiers University Medical Center, Poitiers, France; Institute of Functional Genomics, INSERM 1191, University of Montpellier, France; University of Montpellier, Montpellier, France
| | - Arthur Coget
- I2FH, Institut d'Imagerie Fonctionnelle Humaine, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France; Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
| | - Anne-Laure Lemaitre
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
| | - Sylvie Moritz-Gasser
- Institute of Functional Genomics, INSERM 1191, University of Montpellier, France; University of Montpellier, Montpellier, France; Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
| | - Hugues Duffau
- Institute of Functional Genomics, INSERM 1191, University of Montpellier, France; University of Montpellier, Montpellier, France; Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
| | - Guillaume Herbet
- Institute of Functional Genomics, INSERM 1191, University of Montpellier, France; University of Montpellier, Montpellier, France; Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France.
| |
Collapse
|
20
|
Doyen J, Sunyach MP, Almairac F, Bourg V, Naghavi AO, Duhil de Bénazé G, Claren A, Padovani L, Benezery K, Noël G, Hannoun-Lévi JM, Guedea F, Giralt J, Vidal M, Baudin G, Opitz L, Claude L, Bondiau PY. Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments. Front Oncol 2021; 10:613089. [PMID: 33520724 PMCID: PMC7842185 DOI: 10.3389/fonc.2020.613089] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 11/23/2020] [Indexed: 12/25/2022] Open
Abstract
Background The conventional dose rate of radiation therapy is 0.01–0.05 Gy per second. According to preclinical studies, an increased dose rate may offer similar anti-tumoral effect while dramatically improving normal tissue protection. This study aims at evaluating the early toxicities for patients irradiated with high dose rate pulsed proton therapy (PT). Materials and Methods A single institution retrospective chart review was performed for patients treated with high dose rate (10 Gy per second) pulsed proton therapy, from September 2016 to April 2020. This included both benign and malignant tumors with ≥3 months follow-up, evaluated for acute (≤2 months) and subacute (>2 months) toxicity after the completion of PT. Results There were 127 patients identified, with a median follow up of 14.8 months (3–42.9 months). The median age was 55 years (1.6–89). The cohort most commonly consisted of benign disease (55.1%), cranial targets (95.1%), and were treated with surgery prior to PT (56.7%). There was a median total PT dose of 56 Gy (30–74 Gy), dose per fraction of 2 Gy (1–3 Gy), and CTV size of 47.6 ml (5.6–2,106.1 ml). Maximum acute grade ≥2 toxicity were observed in 49 (38.6%) patients, of which 8 (6.3%) experienced grade 3 toxicity. No acute grade 4 or 5 toxicity was observed. Maximum subacute grade 2, 3, and 4 toxicity were discovered in 25 (19.7%), 12 (9.4%), and 1 (0.8%) patient(s), respectively. Conclusion In this cohort, utilizing high dose rate proton therapy (10 Gy per second) did not result in a major decrease in acute and subacute toxicity. Longer follow-up and comparative studies with conventional dose rate are required to evaluate whether this approach offers a toxicity benefit.
Collapse
Affiliation(s)
- Jérôme Doyen
- Université Côte d'Azur, Department of Radiation Oncology, Centre Antoine-Lacassagne, Fédération Claude Lalanne, Nice, France
| | | | - Fabien Almairac
- Department of Neurosurgery, Centre Hospitalier Universitaire, University Côte d'Azur, Nice, France
| | - Véronique Bourg
- Department of Neurology, Centre Hospitalier Universitaire, University Côte d'Azur, Nice, France
| | - Arash O Naghavi
- Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
| | - Gwenaëlle Duhil de Bénazé
- Department of Pediatric Oncology, Centre Hospitalier Universitaire, University Côte d'Azur, Nice, France
| | - Audrey Claren
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France
| | - Laetitia Padovani
- Oncology Radiotherapy Department, CRCM Inserm, UMR1068, CNRS UMR7258, AMU UM105, Genome Instability and Carcinogenesis, Assistance Publique des Hôpitaux de Marseille, Aix-Marseille University, Marseille, France
| | - Karen Benezery
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France
| | - Georges Noël
- Department of Radiation Oncology, Institut de cancérologie Strasbourg Europe (Icans), Strasbourg, France
| | - Jean-Michel Hannoun-Lévi
- Université Côte d'Azur, Department of Radiation Oncology, Centre Antoine-Lacassagne, Fédération Claude Lalanne, Nice, France
| | - Ferran Guedea
- Radiation Oncology Department, Institut Català d'Oncologia (ICO) and University of Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain
| | - Jordi Giralt
- Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Marie Vidal
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Nice, France
| | - Guillaume Baudin
- Department of Radiology, Centre Antoine-Lacassagne, Nice, France
| | - Lucas Opitz
- Department of Anesthesiology, Centre Antoine-Lacassagne, Nice, France
| | - Line Claude
- Department of Radiotherapy, Léon Bérard Cancer Center, Lyon, France
| | | |
Collapse
|
21
|
Arzoine J, Levé C, Pérez-Hick A, Goodden J, Almairac F, Aubrun S, Gayat E, Freyschlag CF, Vallée F, Mandonnet E, Madadaki C. Anesthesia management for low-grade glioma awake surgery: a European Low-Grade Glioma Network survey. Acta Neurochir (Wien) 2020; 162:1701-1707. [PMID: 32128618 DOI: 10.1007/s00701-020-04274-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Accepted: 02/20/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND Awake surgery has become a key treatment of diffuse low-grade gliomas (DLGG) and is divided in three main phases: opening, tumor resection - during which the patient needs to be fully awake - and closure. The anesthetic management of awake neurosurgery is a challenge, and there are currently no guidelines. OBJECTIVE The objective of the survey was to explore differences and commonalities regarding the anesthetic management of awake DLGG surgery within the European Low-Grade Glioma Network (ELGGN) centers. METHODS A form that contained 14 questions about the anesthetic management was sent to 28 centers in May 2015. RESULTS Twenty centers responded. During the opening and closing non-awake periods, 56% of teams chose general anesthesia with mechanical ventilation for at least one period (asleep-awake-asleep, SAS protocol), and 44% monitored anesthesia care including sedation without mechanical ventilation (MAC protocol). In case of SAS, all the teams chose intravenous anesthesia, 82% used laryngeal mask instead of endotracheal intubation during the opening sequence, and 71% during closure. Local and regional anesthesia was practiced by all the teams. The most frequently reported cause of pain was dural and cerebral vessels manipulation (77%). Pain management was mostly based on paracetamol (70%) and remifentanil (55%). CONCLUSION Our survey showed that there was an equivalent proportion of centers using SAS or MAC protocols in the anesthetic management of awake surgery in ELGGN centers. The advantages and disadvantages of each anesthesia protocol were reviewed.
Collapse
Affiliation(s)
- Jeremy Arzoine
- Department of Anesthesiology and Critical Care, St-Louis-Lariboisière-Fernand Widal University Hospitals, APHP, Paris, France
| | - Charlotte Levé
- Department of Anesthesiology and Critical Care, St-Louis-Lariboisière-Fernand Widal University Hospitals, APHP, Paris, France
- INSERM UMR-942, Paris, France
| | | | - John Goodden
- Department of Neurosurgery, Leeds General Infirmary, Leeds, UK
| | - Fabien Almairac
- Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France
| | - Sylvie Aubrun
- Department of Anesthesiology and Critical Care, St-Louis-Lariboisière-Fernand Widal University Hospitals, APHP, Paris, France
| | - Etienne Gayat
- Department of Anesthesiology and Critical Care, St-Louis-Lariboisière-Fernand Widal University Hospitals, APHP, Paris, France
- University Paris 7, Paris, France
| | | | - Fabrice Vallée
- Department of Anesthesiology and Critical Care, St-Louis-Lariboisière-Fernand Widal University Hospitals, APHP, Paris, France
- INSERM UMR-942, Paris, France
| | - Emmanuel Mandonnet
- University Paris 7, Paris, France.
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France.
- Frontlab, Institut du Cerveau et de la Moelle épinière, Inserm U 1127, CNRS UMR 7225, Paris, France.
| | - Catherine Madadaki
- Department of Anesthesiology and Critical Care, St-Louis-Lariboisière-Fernand Widal University Hospitals, APHP, Paris, France
| |
Collapse
|
22
|
Martel A, Farah E, Zmuda M, Almairac F, Jacomet PV, Galatoire O. Autologous dermis graft versus conchal cartilage graft for managing lower eyelid retraction: A comparative study. Eur J Ophthalmol 2020; 31:1733-1740. [PMID: 32530712 DOI: 10.1177/1120672120934408] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
PURPOSE Lower eyelid management is challenging. The conchal cartilage is often considered a spacer of choice for treating lower eyelid retraction. However, dermis graft has also recently been shown to be a viable spacer. The aim of this study was to compare the efficacy of dermis graft to that of conchal cartilage graft in this indication. METHODS A retrospective comparative study was conducted in patients who underwent lower eyelid lengthening with autologous dermis graft (group 1) or autologous conchal cartilage graft (group 2). The main outcome measure was the reduction in inferior scleral show (ISS) assessed by three independent masked surgeons. Secondary outcome measures was the assessment of lagophthalmos and corneal keratitis. Complications were also recorded. RESULTS Twenty-five eyelids of 23 patients were included: 11 and 14 eyelids, respectively in group 1 (dermis graft) and group 2 (conchal cartilage graft). Patient mean follow-up was 12.3 (±12.5) and 7.1 (±7.7) months, respectively. No statistical differences in postoperative ISS reduction, lagophthalmos and exposure keratitis was observed (p = 0.540, p = 0.946, p = 0.934, respectively). Three patients experienced a grade I Clavien-Dindo complication in group 1 and one patient experienced a grade II complication in group 2 (p = 0.540). CONCLUSION Autologous dermis grafts and conchal cartilage grafts provide favorable outcomes without major complications.
Collapse
Affiliation(s)
- Arnaud Martel
- Oculoplastic Department, Rothschild Foundation, Paris, France.,Ophthalmology Department, University Hospital of Nice, Nice, France
| | - Edgar Farah
- Oculoplastic Department, Rothschild Foundation, Paris, France
| | - Matthieu Zmuda
- Oculoplastic Department, Rothschild Foundation, Paris, France
| | - Fabien Almairac
- Neurosurgery Department, University Hospital of Nice, Nice, France
| | | | | |
Collapse
|
23
|
Almairac F, Turchi L, Sakakini N, Debruyne DN, Elkeurti S, Gjernes E, Polo B, Bianchini L, Fontaine D, Paquis P, Chneiweiss H, Junier MP, Verrando P, Burel-Vandenbos F, Virolle T. ERK-Mediated Loss of miR-199a-3p and Induction of EGR1 Act as a "Toggle Switch" of GBM Cell Dedifferentiation into NANOG- and OCT4-Positive Cells. Cancer Res 2020; 80:3236-3250. [PMID: 32366479 DOI: 10.1158/0008-5472.can-19-0855] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 01/27/2020] [Accepted: 04/29/2020] [Indexed: 11/16/2022]
Abstract
There is great interest in understanding how the cancer stem cell population may be maintained in solid tumors. Here, we show that tumor cells exhibiting stem-like properties and expression of pluripotency markers NANOG and OCT4 can arise from original differentiated tumor cells freshly isolated from human glioblastomas (GBM) and that have never known any serum culture conditions. Induction of EGR1 by EGFR/ERK signaling promoted cell conversion from a less aggressive, more differentiated cellular state to a self-renewing and strongly tumorigenic state, expressing NANOG and OCT4. Expression of these pluripotency markers occurred before the cells re-entered the cell cycle, demonstrating their capacity to change and dedifferentiate without any cell divisions. In differentiated GBM cells, ERK-mediated repression of miR-199a-3p induced EGR1 protein expression and triggered dedifferentiation. Overall, this signaling pathway constitutes an ERK-mediated "toggle switch" that promotes pluripotency marker expression and stem-like features in GBM cells. SIGNIFICANCE: This study defines an ERK-mediated molecular mechanism of dedifferentiation of GBM cells into a stem-like state, expressing markers of pluripotency.See related commentary by Koncar and Agnihotri, p. 3195.
Collapse
Affiliation(s)
- Fabien Almairac
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France.,Service de Neurochirurgie, Hôpital Pasteur, CHU de Nice, France
| | - Laurent Turchi
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France.,DRCI, CHU de Nice, France
| | - Nathalie Sakakini
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France
| | | | - Sarah Elkeurti
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France
| | - Elisabet Gjernes
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France
| | - Beatrice Polo
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France
| | - Laurence Bianchini
- Laboratory of Solid Tumor Genetics, Université Côte d'Azur (UCA), CNRS UMR7284, INSERM U1081, Institute for Research on Cancer and Aging, Nice (IRCAN), Nice, France
| | - Denys Fontaine
- Service de Neurochirurgie, Hôpital Pasteur, CHU de Nice, France
| | - Philippe Paquis
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France.,Service de Neurochirurgie, Hôpital Pasteur, CHU de Nice, France
| | - Herve Chneiweiss
- CNRS UMR8246 Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris, France.,Inserm U1130, Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris, France.,Sorbonne University, Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris, France
| | - Marie-Pierre Junier
- CNRS UMR8246 Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris, France.,Inserm U1130, Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris, France.,Sorbonne University, Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris, France
| | - Patrick Verrando
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France
| | - Fanny Burel-Vandenbos
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France.,Service d'Anatomopathologie, Hôpital Pasteur, CHU de Nice, France
| | - Thierry Virolle
- Université Côte D'Azur, CNRS, INSERM, Institut de Biologie Valrose, Nice, France.
| |
Collapse
|
24
|
Flory V, Mondot L, Burel-Vandenbos F, Denis E, Chanalet S, Almairac F, Bourg V, Goya-Outi J, Frouin F, Fontaine D, Lebrun-Frenay C, Orlhac F. Analyse radiomique des gliomes de bas grades : une étude rétrospective. J Neuroradiol 2020. [DOI: 10.1016/j.neurad.2019.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Martel A, Oberic A, Moulin A, Zografos L, Bellini L, Almairac F, Hamedani M. Orbital exenteration and conjunctival melanoma: a 14-year study at the Jules Gonin Eye Hospital. Eye (Lond) 2020; 34:1897-1902. [PMID: 31959885 PMCID: PMC7608475 DOI: 10.1038/s41433-020-0767-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2019] [Revised: 01/10/2020] [Accepted: 01/10/2020] [Indexed: 02/06/2023] Open
Abstract
Purpose To report our 14-year experience with orbital exenteration and assess risk factors for poor prognosis by focusing on conjunctival melanoma. Patients and method A retrospective study was conducted in our tertiary care centre (Jules Gonin Eye Hospital, Lausanne, Switzerland) between 2003 and 2017. Inclusion criteria were patients aged ≥18 years with a follow-up >12 months, without metastatic spread at the time of surgery. Data recorded were age, gender, tumour histology, surgical technique, postoperative complications, surgical margin status, local recurrence, postoperative radiation beam therapy and metastatic status. Results Twenty-five patients with a mean age of 63.2 years (38–92) were included. Conjunctival melanoma was the most frequently identified tumour (n = 14, 56%) followed by conjunctival squamous cell carcinoma (n = 4, 16%), sebaceous carcinoma (n = 3, 12%), choroidal melanoma (n = 2, 8%) and basal cell carcinoma (n = 2, 8%). Eighteen tumours (72%) originated from the conjunctival tissue. Clear surgical margins were achieved in 21 (84%) patients. Fourteen (56%) patients experienced distant metastases and died from metastatic spread after a mean follow-up of 52.3 months (6–120). The 1-, 3- and 5-year overall survival (OS) was 96%, 72% and 60%, respectively. In the univariate analysis, positive surgical margins, local recurrence and metachronous metastases were associated with a decreased OS (p = 0.002, p = 0.005 and p = 0.007, respectively). In the multivariate analysis, positive surgical margins and metachronous metastases were also associated with a decreased OS (p = 0.02 and p = 0.042, respectively). Conjunctival melanoma was not associated with a poorer prognosis (p = 0.280). Conclusion Free surgical margins are needed to increase OS. To achieve clearer surgical margins, neoadjuvant targeted therapies/immunotherapies may be considered.
Collapse
Affiliation(s)
- A Martel
- Ophthalmology Department, University Hospital of Nice, Nice, France. .,University of Cote d'Azur, Nice, France. .,Inserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 1, Nice, France.
| | - A Oberic
- Ophthalmology Department, Jules Gonin Eye Hospital, Lausanne, Switzerland
| | - A Moulin
- Ophthalmology Department, Jules Gonin Eye Hospital, Lausanne, Switzerland
| | - L Zografos
- Ophthalmology Department, Jules Gonin Eye Hospital, Lausanne, Switzerland
| | - L Bellini
- Inserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 1, Nice, France
| | - F Almairac
- University of Cote d'Azur, Nice, France.,Neurosurgery Department, University Hospital of Nice, Nice, France
| | - M Hamedani
- Ophthalmology Department, Jules Gonin Eye Hospital, Lausanne, Switzerland
| |
Collapse
|
26
|
Martel A, Oberic A, Bellini L, Almairac F, Moulin A, Hamedani M. Is Implant Placement Performed at the Same Surgical Time as Orbital Exenteration a Viable Procedure? Int J Oral Maxillofac Implants 2020; 35:160–166. [DOI: 10.11607/jomi.7670] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Atallah V, Sumodhee S, Claren A, Natale R, Schiappa R, Gillon P, Doyen J, Paquis P, Almairac F, Sadoul J, Sicurani J, Chevalier N, Hannoun-Levi J, Bondiau P. Stereotactic Radiation Therapy for Pituitary Adenomas: Retrospective Analysis of an Alternative Multi-Fractionated Protocol with Robotic Radiosurgery Including 35 Gy in 5 Fractions. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Martel A, Bougaci N, Lagier J, Almairac F, Dagain A. Post-traumatic orbitorrhea: An underestimated life-threatening complication following anterior skull base fractures. Eur J Ophthalmol 2019; 31:NP123-NP125. [PMID: 31370684 DOI: 10.1177/1120672119867827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Orbitorrhea is defined as a leak of cerebrospinal fluid from a cranio-orbital fistula. It is usually related to anterior skull base trauma. Orbitorrhea is an exceptional and life-threatening condition which should be promptly managed. We herein report the case of a right post-traumatic orbitorrhea following anterior skull base trauma. Conservative treatment was initially attempted. At 6 weeks, recurrence was noted, and the patient underwent neurosurgical management. A few months later, a secondary upper lid retraction was diagnosed and treated by full-thickness skin graft with favourable outcome. To our knowledge, fewer than 30 cases have been previously reported. Ophthalmologists should be aware of this life-threatening condition which could be underestimated.
Collapse
Affiliation(s)
- Arnaud Martel
- Department of Ophthalmology, University Hospital of Nice, Nice, France.,Cote d'AZUR University, Nice, France.,Centre Mediterranéen de Médecine Moléculaire (C3M), Team 1, INSERM, Nice, France
| | - Nassim Bougaci
- Cote d'AZUR University, Nice, France.,Department of Neurosurgery, University Hospital of Nice, Nice, France
| | - Jacques Lagier
- Department of Ophthalmology, University Hospital of Nice, Nice, France
| | - Fabien Almairac
- Cote d'AZUR University, Nice, France.,Department of Neurosurgery, University Hospital of Nice, Nice, France
| | - Arnaud Dagain
- Neurosurgery Department, Sainte Anne Military Teaching Hospital, Toulon, France
| |
Collapse
|
29
|
Darlix A, Mandonnet E, Freyschlag CF, Pinggera D, Forster MT, Voss M, Steinbach J, Loughrey C, Goodden J, Banna G, Di Blasi C, Foroglou N, Hottinger AF, Baron MH, Pallud J, Duffau H, Rutten GJ, Almairac F, Fontaine D, Taillandier L, Pessanha Viegas C, Albuquerque L, von Campe G, Urbanic-Purkart T, Blonski M. Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network. Neurooncol Pract 2019; 6:264-273. [PMID: 31386080 PMCID: PMC6660823 DOI: 10.1093/nop/npy051] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Diffuse low-grade gliomas (DLGGs) are rare and incurable tumors. Whereas maximal safe, functional-based surgical resection is the first-line treatment, the timing and choice of further treatments (chemotherapy, radiation therapy, or combined treatments) remain controversial. METHODS An online survey on the management of DLGG patients was sent to 28 expert centers from the European Low-Grade Glioma Network (ELGGN) in May 2015. It contained 40 specific questions addressing the modalities of use of chemotherapy in these patients. RESULTS The survey demonstrated a significant heterogeneity in practice regarding the initial management of DLGG patients and the use of chemotherapy. Interestingly, radiation therapy combined with the procarbazine, CCNU (lomustine), and vincristine regimen has not imposed itself as the gold-standard treatment after surgery, despite the results of the Radiation Therapy Oncology Group 9802 study. Temozolomide is largely used as first-line treatment after surgical resection for high-risk DLGG patients, or at progression. CONCLUSIONS The heterogeneity in the management of patients with DLGG demonstrates that many questions regarding the postoperative strategy and the use of chemotherapy remain unanswered. Our survey reveals a high recruitment potential within the ELGGN for retrospective or prospective studies to generate new data regarding these issues.
Collapse
Affiliation(s)
- Amélie Darlix
- Department of Medical Oncology, Institut du Cancer de Montpellier, University of Montpellier, France
| | | | | | - Daniel Pinggera
- Department of Neurosurgery, Medical University of Innsbruck, Austria
| | | | - Martin Voss
- Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany
| | - Joachim Steinbach
- Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany
| | | | - John Goodden
- Leeds General Infirmary and North East Paediatric Neuroscience Network, Leeds, United Kingdom
| | - Giuseppe Banna
- Department of Neurosurgery and Gammaknife, Cannizzaro General Hospital, Catania, Italy
| | - Concetta Di Blasi
- Department of Neurosurgery and Gammaknife, Cannizzaro General Hospital, Catania, Italy
| | - Nicolas Foroglou
- Aristotle University of Thessaloniki, Department of Neurosurgery, AHEPA University Hospital, Greece
| | - Andreas F Hottinger
- Departments of Clinical Neurosciences and Oncology, Centre Hospitalier Universitaire Vaudois and Lausanne University, Switzerland
| | | | - Johan Pallud
- Department of Neurosurgery, Sainte-Anne Hospital, Paris, France, and Paris Descartes University, Sorbonne Paris Cité, France
| | - Hugues Duffau
- Inserm, U894, IMA-Brain, Centre de Psychiatrie et Neurosciences, Paris, France
- Department of Neurosurgery, Montpellier University Hospital, France
| | - Geert-Jan Rutten
- Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands
| | - Fabien Almairac
- Department of Neurosurgery, University Hospital of Nice, France
| | - Denys Fontaine
- Department of Neurosurgery, University Hospital of Nice, France
| | - Luc Taillandier
- Department of Neurooncology, Nancy Neurological Hospital, France
| | | | | | - Gord von Campe
- Department of Neurosurgery, Medical University of Graz, Austria
| | | | - Marie Blonski
- Department of Neurooncology, Nancy Neurological Hospital, France
| |
Collapse
|
30
|
Humbert O, Bourg V, Mondot L, Gal J, Bondiau PY, Fontaine D, Barriere J, Saada-Bouzid E, Paquet M, Chardin D, Almairac F, Vandenbos F, Darcourt J. Correction to: 18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions. Eur J Nucl Med Mol Imaging 2019; 46:1581. [PMID: 30980100 DOI: 10.1007/s00259-019-04321-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Jérôme Barriere was inadvertently missing in the original version of this article. He has participated to the study design, protocol writing and inclusion of a significant number of patients.
Collapse
Affiliation(s)
- Olivier Humbert
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France. .,TIRO-UMR E 4320, UCA/CEA, Nice, France. .,Clinical Research and Innovation Office, UCA, Nice, France.
| | - Véronique Bourg
- Department of Neurology, Pasteur 2 University Hospital, UCA, Nice, France
| | - Lydiane Mondot
- Department of Neuroradiology, Pasteur 2 University Hospital, UCA, Nice, France
| | - Jocelyn Gal
- Department of Biostatistics, Centre Antoine-Lacassagne, UCA, Nice, France
| | | | - Denys Fontaine
- Department of Neurosurgery, Pasteur 2 University Hospital, UCA, Nice, France
| | - Jérôme Barriere
- Department of Medical Oncology, Pôle de Santé Saint Jean, Cagnes-sur-Mer, France
| | - Esma Saada-Bouzid
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France
| | - Marie Paquet
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France.,TIRO-UMR E 4320, UCA/CEA, Nice, France
| | - David Chardin
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France
| | - Fabien Almairac
- Department of Neurosurgery, Pasteur 2 University Hospital, UCA, Nice, France
| | - Fanny Vandenbos
- Central Laboratory of Pathology, Pasteur I University Hospital, UCA, Nice, France
| | - Jacques Darcourt
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France.,TIRO-UMR E 4320, UCA/CEA, Nice, France
| |
Collapse
|
31
|
Humbert O, Bourg V, Mondot L, Gal J, Bondiau PY, Fontaine D, Saada-Bouzid E, Paquet M, Chardin D, Almairac F, Vandenbos F, Darcourt J. 18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions. Eur J Nucl Med Mol Imaging 2019; 46:558-568. [PMID: 30612162 DOI: 10.1007/s00259-018-4240-8] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 12/10/2018] [Indexed: 11/26/2022]
Abstract
PURPOSE This study aimed to assess the therapeutic impact and diagnostic accuracy of 18F-DOPA PET/CT in patients with glioblastoma or brain metastases. METHODS Patients with histologically proven glioblastoma or brain metastases were prospectively included in this monocentric clinical trial (IMOTEP). Patients were included either due to a clinical suspicion of relapse or to assess residual tumor infiltration after treatment. Multimodality brain MRI and 18F-DOPA PET were performed. Patients' data were discussed during a Multidisciplinary Neuro-oncology Tumor Board (MNTB) meeting. The discussion was first based on clinical and MRI data, and an initial diagnosis and treatment plan were proposed. Secondly, a new discussion was conducted based on the overall imaging results, including 18F-DOPA PET. A second diagnosis and therapeutic plan were proposed. A retrospective and definitive diagnosis was obtained after a 3-month follow-up and considered as the reference standard. RESULTS One hundred six cases were prospectively investigated by the MNTB. All patients with brain metastases (N = 41) had a clinical suspicion of recurrence. The addition of 18F-DOPA PET data changed the diagnosis and treatment plan in 39.0% and 17.1% of patients' cases, respectively. Concerning patients with a suspicion of recurrent glioblastoma (N = 12), the implementation of 18F-DOPA PET changed the diagnosis and treatment plan in 33.3% of cases. In patients evaluated to assess residual glioblastoma infiltration after treatment (N = 53), 18F-DOPA PET data had a lower impact with only 5.7% (3/53) of diagnostic changes and 3.8% (2/53) of therapeutic plan changes. The definitive reference diagnosis was available in 98/106 patients. For patients with tumor recurrence suspicion, the adjunction of 18F-DOPA PET increased the Younden's index from 0.44 to 0.53 in brain metastases and from 0.2 to 1.0 in glioblastoma, reflecting an increase in diagnostic accuracy. CONCLUSION 18F-DOPA PET has a significant impact on the management of patients with a suspicion of brain tumor recurrence, either glioblastoma or brain metastases, but a low impact when used to evaluate the residual glioblastoma infiltration after a first-line radio-chemotherapy or second-line bevacizumab.
Collapse
Affiliation(s)
- Olivier Humbert
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France.
- TIRO-UMR E 4320, UCA/CEA, Nice, France.
- Clinical Research and Innovation Office, UCA, Nice, France.
| | - Véronique Bourg
- Department of Neurology, Pasteur 2 University Hospital, UCA, Nice, France
| | - Lydiane Mondot
- Department of Neuroradiology, Pasteur 2 University Hospital, UCA, Nice, France
| | - Jocelyn Gal
- Department of Biostatistics, Centre Antoine-Lacassagne, UCA, Nice, France
| | | | - Denys Fontaine
- Department of Neurosurgery, Pasteur 2 University Hospital, UCA, Nice, France
| | - Esma Saada-Bouzid
- Department of Medical Oncology, Centre Antoine-Lacassagne, UCA, Nice, France
| | - Marie Paquet
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France
- TIRO-UMR E 4320, UCA/CEA, Nice, France
| | - David Chardin
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France
| | - Fabien Almairac
- Department of Neurosurgery, Pasteur 2 University Hospital, UCA, Nice, France
| | - Fanny Vandenbos
- Central Laboratory of Pathology, Pasteur I University Hospital, UCA, Nice, France
| | - Jacques Darcourt
- Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France
- TIRO-UMR E 4320, UCA/CEA, Nice, France
| |
Collapse
|
32
|
Sirven-Villaros L, Bourg V, Suissa L, Mondot L, Almairac F, Fontaine D, Paquis P, Burel-VandenBos F, Frenay M, Thomas P, Lebrun-Frenay C. Bevacizumab: Is the lower the better for glioblastoma patients in progression? Bull Cancer 2018; 105:1135-1146. [DOI: 10.1016/j.bulcan.2018.07.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Revised: 07/04/2018] [Accepted: 07/05/2018] [Indexed: 10/28/2022]
|
33
|
Almairac F, Fontaine D, Demarcy T, Delingette H, Beuil S, Raffaelli C. Motor cortex neurovascular coupling: inputs from ultra-high-frequency ultrasound imaging in humans. J Neurosurg 2018; 131:1-7. [PMID: 30497179 DOI: 10.3171/2018.5.jns18754] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Accepted: 05/31/2018] [Indexed: 01/13/2023]
Abstract
OBJECTIVE Neurovascular coupling reflects the link between neural activity and changes in cerebral blood flow. Despite many technical advances in functional exploration of the brain, including functional MRI, there are only a few reports of direct evidence of neurovascular coupling in humans. The authors aimed to explore, for the first time in humans, the local cerebral blood flow of the primary motor cortex using ultra-high-frequency ultrasound (UHF-US) Doppler imaging to detect low blood flow velocity (1 mm/sec). METHODS Four consecutive patients underwent awake craniotomy for glioma resection using cortical direct electrostimulation for brain mapping. The primary motor cortical area eliciting flexion of the contralateral forearm was identified. UHF-US color Doppler imaging of this cortical area was acquired at rest, during repeated spontaneous forearm flexion, and immediately after the movement's termination. In each condition, the surface areas of the detectable vessels were measured after extraction of non-zero-velocity colored pixels and summed. RESULTS During movement, local cerebral blood flow increased significantly by 14.4% (range 5%-30%) compared with baseline. Immediately after the termination of movements, the local hyperemia decreased significantly by 8.6% (range 1.9%-15.7%). CONCLUSIONS To the authors' knowledge, this study is the first to provide a real-time demonstration of the neurovascular coupling in the human cortex by ultrasound imaging. They assume that UHF-US may be used to gather original and advanced data on brain functioning, which could be used to help in the identification of functional cortical areas during brain surgery.Clinical trial registration no.: NCT03179176 (clinicaltrials.gov).
Collapse
Affiliation(s)
| | - Denys Fontaine
- Departments of1Neurosurgery and
- 2FHU INOVPAIN, CHU de Nice, Université Cote d'Azur, Nice; and
| | - Thomas Demarcy
- 3Asclepios Research Team, INRIA Sophia Antipolis-Mediterranée, France
| | - Hervé Delingette
- 3Asclepios Research Team, INRIA Sophia Antipolis-Mediterranée, France
| | - Stéphanie Beuil
- 4Ultra-Sound Imaging, CHU de Nice, Université Cote d'Azur, Nice
| | | |
Collapse
|
34
|
Almairac F, Duffau H, Herbet G. Contralesional macrostructural plasticity of the insular cortex in patients with glioma: A VBM study. Neurology 2018; 91:e1902-e1908. [PMID: 30305447 DOI: 10.1212/wnl.0000000000006517] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Accepted: 08/01/2018] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To assess the homotopic structural plasticity in case of unilateral damage of the insula. METHODS To detect changes in gray matter volumes of the contralesional insula from structural MRIs, we used voxel-based morphometry (VBM) in a sample of 84 patients with a diffuse low-grade glioma invading the left insula (insL group; n = 47) or the right insula (insR group; n = 37). RESULTS The region of interest-based VBM analysis highlighted a large cluster of voxels with gray matter volume increase in the contralesional insula in both patient groups (k = 2,214 voxels for insL and k = 879 voxels for insR, p < 0.05, family-wise error corrected) compared with 24 age-matched healthy controls. Gray matter volume was increased for the entire insula (t 69 = 3.63, p = 0.0016 for insL; t 59 = 3.54, p = 0.0024 for insR, Bonferroni corrected), whereas no significant changes were found in 2 control regions for both patient groups. Furthermore, an increase of 24.6% and 31.6% in the gray matter volume was observed in the insula-related VBM cluster for insL and insR patients, respectively, compared with healthy controls (t 69 = 7.39, p = 2.59 × 10-10 and t 59 = 7.51, p = 3.61 × 10-10). CONCLUSIONS The reported results demonstrate that slow-growing but massive lesion infiltration of the insula induces marked increase of gray matter volume in the contralateral one. Our findings give support for a homotopic reorganization that might be a physiologic basis for the high level of functional compensation observed in patients with glioma.
Collapse
Affiliation(s)
- Fabien Almairac
- From the Department of Neurosurgery (F.A.), Pasteur 2 Hospital, Nice University Medical Center, Université Côte d'Azur; Department of Neurosurgery (H.D., G.H.), Gui de Chauliac Hospital, and Institute for Neurosciences of Montpellier (H.D., G.H.), INSERM 1051, Team "Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors," Saint Eloi Hospital, Montpellier University Medical Center; and University of Montpellier (H.D., G.H.), France
| | - Hugues Duffau
- From the Department of Neurosurgery (F.A.), Pasteur 2 Hospital, Nice University Medical Center, Université Côte d'Azur; Department of Neurosurgery (H.D., G.H.), Gui de Chauliac Hospital, and Institute for Neurosciences of Montpellier (H.D., G.H.), INSERM 1051, Team "Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors," Saint Eloi Hospital, Montpellier University Medical Center; and University of Montpellier (H.D., G.H.), France
| | - Guillaume Herbet
- From the Department of Neurosurgery (F.A.), Pasteur 2 Hospital, Nice University Medical Center, Université Côte d'Azur; Department of Neurosurgery (H.D., G.H.), Gui de Chauliac Hospital, and Institute for Neurosciences of Montpellier (H.D., G.H.), INSERM 1051, Team "Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors," Saint Eloi Hospital, Montpellier University Medical Center; and University of Montpellier (H.D., G.H.), France.
| |
Collapse
|
35
|
Freyschlag CF, Krieg SM, Kerschbaumer J, Pinggera D, Forster MT, Cordier D, Rossi M, Miceli G, Roux A, Reyes A, Sarubbo S, Smits A, Sierpowska J, Robe PA, Rutten GJ, Santarius T, Matys T, Zanello M, Almairac F, Mondot L, Jakola AS, Zetterling M, Rofes A, von Campe G, Guillevin R, Bagatto D, Lubrano V, Rapp M, Goodden J, De Witt Hamer PC, Pallud J, Bello L, Thomé C, Duffau H, Mandonnet E. Imaging practice in low-grade gliomas among European specialized centers and proposal for a minimum core of imaging. J Neurooncol 2018; 139:699-711. [PMID: 29992433 PMCID: PMC6132968 DOI: 10.1007/s11060-018-2916-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Accepted: 05/29/2018] [Indexed: 11/25/2022]
Abstract
OBJECTIVE Imaging studies in diffuse low-grade gliomas (DLGG) vary across centers. In order to establish a minimal core of imaging necessary for further investigations and clinical trials in the field of DLGG, we aimed to establish the status quo within specialized European centers. METHODS An online survey composed of 46 items was sent out to members of the European Low-Grade Glioma Network, the European Association of Neurosurgical Societies, the German Society of Neurosurgery and the Austrian Society of Neurosurgery. RESULTS A total of 128 fully completed surveys were received and analyzed. Most centers (n = 96, 75%) were academic and half of the centers (n = 64, 50%) adhered to a dedicated treatment program for DLGG. There were national differences regarding the sequences enclosed in MRI imaging and use of PET, however most included T1 (without and with contrast, 100%), T2 (100%) and TIRM or FLAIR (20, 98%). DWI is performed by 80% of centers and 61% of centers regularly performed PWI. CONCLUSION A minimal core of imaging composed of T1 (w/wo contrast), T2, TIRM/FLAIR, PWI and DWI could be identified. All morphologic images should be obtained in a slice thickness of ≤ 3 mm. No common standard could be obtained regarding advanced MRI protocols and PET. IMPORTANCE OF THE STUDY We believe that our study makes a significant contribution to the literature because we were able to determine similarities in numerous aspects of LGG imaging. Using the proposed "minimal core of imaging" in clinical routine will facilitate future cooperative studies.
Collapse
Affiliation(s)
- Christian F Freyschlag
- Department of Neurosurgery, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
| | - Sandro M Krieg
- Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Johannes Kerschbaumer
- Department of Neurosurgery, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
| | - Daniel Pinggera
- Department of Neurosurgery, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
| | | | - Dominik Cordier
- Department of Neurosurgery, Universitätsspital Basel, Basel, Switzerland
| | - Marco Rossi
- Neurosurgical Oncology Unit, Humanitas Research Hospital, IRCCS, Milan, Italy
| | - Gabriele Miceli
- Center for Mind/Brain Sciences, University of Trento, Rovereto, Italy
| | - Alexandre Roux
- Department of Neurosurgery, Sainte-Anne Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- Inserm U894, IMA-Brain, Centre de Psychiatrie et Neurosciences, Paris, France
| | - Andrés Reyes
- European Master's in Clinical Linguistics (EMCL), University of Groningen, Groningen, The Netherlands
- EMCL University of Potsdam, Potsdam, Germany
- Neuroscience Institute, and Laboratory of Experimental Psychology, Faculty of Psychology, El Bosque University, Bogotá, Colombia
| | - Silvio Sarubbo
- Division of Neurosurgery, Structural and Functional Connectivity Lab Project, "S. Chiara" Hospital, APSS, Trento, Italy
| | - Anja Smits
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden
| | - Joanna Sierpowska
- Cognition and Brain Plasticity Unit, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, Barcelona, Spain
- Department of Cognition, Development and Education Psychology, Barcelona, Spain
| | - Pierre A Robe
- Department of Neurology and Neurosurgery, Rudolf Magnus Brain Institute, University Medical Center of Utrecht, Utrecht, The Netherlands
| | - Geert-Jan Rutten
- Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands
| | - Thomas Santarius
- Department of Neurosurgery, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK
| | - Tomasz Matys
- Department of Radiology, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK
| | - Marc Zanello
- Department of Neurosurgery, Sainte-Anne Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- Inserm U894, IMA-Brain, Centre de Psychiatrie et Neurosciences, Paris, France
| | - Fabien Almairac
- Neurosurgery Department, Hôpital Pasteur 2, University Hospital of Nice, Nice, France
| | - Lydiane Mondot
- Radiology Department, Hôpital Pasteur 2, University Hospital of Nice, Nice, France
| | - Asgeir S Jakola
- Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden
- Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden
| | - Maria Zetterling
- Department of Neurosurgery, Institution of Neuroscience, Uppsala University Hospital, Uppsala, Sweden
| | - Adrià Rofes
- Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland
- Department of Cognitive Science, Johns Hopkins University, Baltimore, USA
| | - Gord von Campe
- Department of Neurosurgery, Medical University Graz, Graz, Austria
| | - Remy Guillevin
- DACTIM, UMR CNRS 7348, Université de Poitiers et CHU de Poitiers, Poitiers, France
| | - Daniele Bagatto
- Neuroradiology Department, University Hospital Santa Maria della Misericordia, Udine, Italy
| | - Vincent Lubrano
- Department of Neurosurgery, CHU Toulouse, Toulouse, France
- ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France
| | - Marion Rapp
- Department of Neurosurgery, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - John Goodden
- Department of Neurosurgery, The General Infirmary at Leeds, Leeds, West Yorkshire, UK
| | | | - Johan Pallud
- Department of Neurosurgery, Sainte-Anne Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- Inserm U894, IMA-Brain, Centre de Psychiatrie et Neurosciences, Paris, France
| | - Lorenzo Bello
- Neurosurgical Oncology Unit, Humanitas Research Hospital, IRCCS, Milan, Italy
| | - Claudius Thomé
- Department of Neurosurgery, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria
| | - Hugues Duffau
- Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier, France
- Institute of Neuroscience of Montpellier, INSERM U1051, University of Montpellier, Montpellier, France
| | - Emmanuel Mandonnet
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France
- University Paris 7, Paris, France
- IMNC, UMR 8165, Orsay, France
| |
Collapse
|
36
|
Herbet G, Moritz-Gasser S, Lemaitre AL, Almairac F, Duffau H. Functional compensation of the left inferior longitudinal fasciculus for picture naming. Cogn Neuropsychol 2018; 36:140-157. [DOI: 10.1080/02643294.2018.1477749] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Affiliation(s)
- Guillaume Herbet
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
- Institute for Neuroscience of Montpellier, INSERM U1051 (Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors research group), Montpellier, France
- Department of Medicine, University of Montpellier, Montpellier, France
| | - Sylvie Moritz-Gasser
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
- Institute for Neuroscience of Montpellier, INSERM U1051 (Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors research group), Montpellier, France
- Department of Medicine, University of Montpellier, Montpellier, France
| | - Anne-Laure Lemaitre
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
- Department of Psychology, University of Lille, Lille, France
| | - Fabien Almairac
- Department of Neurosurgery, Nice University Medical Center, Nice, France
| | - Hugues Duffau
- Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France
- Institute for Neuroscience of Montpellier, INSERM U1051 (Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors research group), Montpellier, France
- Department of Medicine, University of Montpellier, Montpellier, France
| |
Collapse
|
37
|
Terrier LM, Bauchet L, Rigau V, Amelot A, Zouaoui S, Filipiak I, Caille A, Almairac F, Aubriot-Lorton MH, Bergemer-Fouquet AM, Bord E, Cornu P, Czorny A, Dam Hieu P, Debono B, Delisle MB, Emery E, Farah W, Gauchotte G, Godfraind C, Guyotat J, Irthum B, Janot K, Le Reste PJ, Liguoro D, Loiseau H, Lot G, Lubrano V, Mandonnet E, Menei P, Metellus P, Milin S, Muckenstrum B, Roche PH, Rousseau A, Uro-Coste E, Vital A, Voirin J, Wager M, Zanello M, François P, Velut S, Varlet P, Figarella-Branger D, Pallud J, Zemmoura I. Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database. Neuro Oncol 2018; 19:678-688. [PMID: 28453747 DOI: 10.1093/neuonc/now186] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 07/21/2016] [Indexed: 12/11/2022] Open
Abstract
Background Anaplastic gangliogliomas (GGGs) are rare tumors whose natural history is poorly documented. We aimed to define their clinical and imaging features and to identify prognostic factors. Methods Consecutive cases of anaplastic GGGs in adults prospectively entered into the French Brain Tumor Database between March 2004 and April 2014 were screened. After diagnosis was confirmed by pathological review, clinical, imaging, therapeutic, and outcome data were collected retrospectively. Results Forty-three patients with anaplastic GGG (median age, 49.4 y) from 18 centers were included. Presenting symptoms were neurological deficit (37.2%), epileptic seizure (37.2%), or increased intracranial pressure (25.6%). Typical imaging findings were unifocal location (94.7%), contrast enhancement (88.1%), central necrosis (43.2%), and mass effect (47.6%). Therapeutic strategy included surgical resection (95.3%), adjuvant radiochemotherapy (48.8%), or radiotherapy alone (27.9%). Median progression-free survival (PFS) and overall survival (OS) were 8.0 and 24.7 months, respectively. Three- and 5-year tumor recurrence rates were 69% and 100%, respectively. The 5-year survival rate was 24.9%. Considering unadjusted significant prognostic factors, tumor midline crossing and frontal location were associated with shorter OS. Temporal and parietal locations were associated with longer and shorter PFS, respectively. None of these factors remained statistically significant in multivariate analysis. Conclusions We report a large series providing clinical, imaging, therapeutic, and prognostic features of adult patients treated for an intracerebral anaplastic GGG. Our results show that pathological diagnosis is difficult, that survivals are only slightly better than for glioblastomas, and that complete surgical resection followed with adjuvant chemoradiotherapy offers longer survival.
Collapse
Affiliation(s)
- Louis-Marie Terrier
- CHRU de Tours, Service de Neurochirurgie, Tours, France.,Université François-Rabelais de Tours, Inserm, Imagerie et Cerveau UMR U930, Tours, France
| | - Luc Bauchet
- Department of Neurosurgery and INSERM U1051, Hôpital Saint Eloi - Gui de Chauliac, Montpellier, France.,French Brain Tumor DataBase, ICM, Montpellier, France
| | - Valérie Rigau
- French Brain Tumor DataBase, ICM, Montpellier, France.,Department of Neuropathology and INSERM U1051, Hôpital Saint Eloi - Gui de Chauliac, Montpellier, France
| | - Aymeric Amelot
- Department of Neurosurgery, Hôpital La Pitié Salpétrière, APHP, Paris, France
| | - Sonia Zouaoui
- Department of Neurosurgery and INSERM U1051, Hôpital Saint Eloi - Gui de Chauliac, Montpellier, France.,French Brain Tumor DataBase, ICM, Montpellier, France
| | - Isabelle Filipiak
- Plateforme CIRE, UMR-PRC, 37380 Nouzilly, Centre INRA Val de Loire, France
| | - Agnès Caille
- Université François-Rabelais de Tours, Tours, France.,Inserm, CIC 1415, CHRU de Tours, Tours, France.,Service de Neurochirurgie, CHU Jean-Minjoz, 3 boulevard Alexander-Fleming, Besançon cedex, France
| | - Fabien Almairac
- Department of Neurosurgery, Hôpital Pasteur, University Hospital Center, 06000, Nice, France
| | - Marie-Hélène Aubriot-Lorton
- Department of Pathology, Hôpital François Mitterand, CHU de Dijon, 14 rue Paul Gaffarel, 21000 Dijon, France
| | | | - Eric Bord
- Department of Neurosurgery and Neurotraumatology, Nantes University Hospital, Nantes, France
| | - Philippe Cornu
- Department of Neurosurgery, Hôpital La Pitié Salpétrière, APHP, Paris, France
| | - Alain Czorny
- Service de Neurochirurgie, CHU Jean-Minjoz, 3 boulevard Alexander-Fleming, Besançon cedex, France
| | - Phong Dam Hieu
- Department of Neurosurgery, CHU de la Cavale Blanche, Brest, France
| | - Bertrand Debono
- Department of Neurosurgery, Cèdres Hospital, Toulouse, France
| | - Marie-Bernadette Delisle
- Laboratoire Universitaire d'Anatomie Patholgique, Neuropathologie humaine et expérimentale, CHU Rangueil, Toulouse, France
| | - Evelyne Emery
- Department of Neurosurgery, University Hospital of Caen, Caen, France
| | - Walid Farah
- Service de Neurochirurgie, Hôpital François Mitterand, CHU de Dijon, 14 rue Paul Gaffarel, 21000 Dijon, France
| | - Guillaume Gauchotte
- Department of Pathology, CHU Nancy and INSERM U954, Faculty of Medicine, Université de Lorraine, France
| | | | - Jacques Guyotat
- Department of Neurosurgery, Neurological Hospital, Lyon, France
| | - Bernard Irthum
- Service de neurochirurgie, hôpital Gabriel-Montpied, CHU de Clermont-Ferrand, 58, rue Montalembert, 63003 Clermont-Ferrand, France
| | - Kevin Janot
- Service de Neuroradiologie, CHRU de Tours, Tours, France
| | - Pierre-Jean Le Reste
- Department of Neurosurgery, University Hospital Pontchaillou, 2, Rue Henri Le Guilloux, 35000, Rennes, France
| | - Dominique Liguoro
- Service de neurochirurgie A, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - Hugues Loiseau
- Université de Bordeaux - Service de Neurochirurgie B, hôpital Pellegrin Tripode, Bordeaux, France
| | - Guillaume Lot
- Department of Neurosurgery, Fondation Ophtalmologique Rothschild, Paris, France
| | - Vincent Lubrano
- Service de neurochirurgie, hôpital de Rangueil, CHU de Toulouse, 1, avenue du Professeur-Jean-Poulhès, TSA, Toulouse, France
| | | | - Philippe Menei
- Département de neurochirurgie, CHU d'Angers, 4, rue Larrey, 49940 Angers cedex 9, France
| | - Philippe Metellus
- Département de neurochirurgie, Aix-Marseille université, CHU Timone, Assistance publique-Hôpitaux de Marseille, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France
| | - Serge Milin
- Department of Pathology, CHU de Poitiers, Hôpital la Milétrie, Poitiers, France
| | | | - Pierre-Hugues Roche
- Service de Neurochirurgie, Hôpital Nord, APHM, University Hospital of Marseille Aix-Marseille Univ, Marseille, France
| | - Audrey Rousseau
- Département de Pathologie Cellulaire et Tissulaire, Centre Hospitalo-universitaire d'Angers, 4 rue Larrey, Angers Cedex, France
| | - Emmanuelle Uro-Coste
- CHU Toulouse, Hôpital de Rangueil, Service d'Anatomie et Cytologie Pathologique, Toulouse, France
| | - Anne Vital
- Bordeaux Institute of Neuroscience, CNRS UMR 5227, F-33076, Bordeaux, France
| | - Jimmy Voirin
- Department of Neurosurgery, Strasbourg-Colmar Hospital, France
| | - Michel Wager
- Department of Neurosurgery, Imaging Laboratory, University Hospital Poitiers, 2 Rue de La Miletrie, Poitiers Cedex, France
| | - Marc Zanello
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Department of Neurosurgery, Sainte-Anne Hospital, Paris, France
| | | | - Stéphane Velut
- CHRU de Tours, Service de Neurochirurgie, Tours, France.,Université François-Rabelais de Tours, Inserm, Imagerie et Cerveau UMR U930, Tours, France
| | - Pascale Varlet
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Department of Neuropathology, Sainte-Anne Hospital, Paris, France
| | | | - Johan Pallud
- Paris Descartes University, Sorbonne Paris Cité, Paris, France.,Department of Neurosurgery, Sainte-Anne Hospital, Paris, France
| | - Ilyess Zemmoura
- CHRU de Tours, Service de Neurochirurgie, Tours, France.,Université François-Rabelais de Tours, Inserm, Imagerie et Cerveau UMR U930, Tours, France
| | | |
Collapse
|
38
|
Fontaine D, Almairac F, Santucci S, Fernandez C, Dallel R, Pallud J, Lanteri-Minet M. Dural and pial pain-sensitive structures in humans: new inputs from awake craniotomies. Brain 2018; 141:1040-1048. [DOI: 10.1093/brain/awy005] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Accepted: 11/23/2017] [Indexed: 11/14/2022] Open
Affiliation(s)
- Denys Fontaine
- Department of Neurosurgery, CHU de Nice, Université Cote d’Azur, Nice, France
- Université Cote d’Azur, FHU INOVPAIN, CHU de Nice, Nice, France
| | - Fabien Almairac
- Department of Neurosurgery, CHU de Nice, Université Cote d’Azur, Nice, France
| | - Serena Santucci
- Department of Neurosurgery, CHU de Nice, Université Cote d’Azur, Nice, France
- Université Cote d’Azur, FHU INOVPAIN, CHU de Nice, Nice, France
| | - Charlotte Fernandez
- Department of Neurosurgery, CHU de Nice, Université Cote d’Azur, Nice, France
| | - Radhouane Dallel
- INSERM/UdA, U1107, Neuro-Dol, Auvergne University, Clermont-Ferrand, France
| | - Johan Pallud
- Department of Neurosurgery, Hopital St Anne, Paris, France
- Paris Descartes University, Sorbonne Paris Cité, Paris, France
- Inserm, U894, Centre Psychiatrie et Neurosciences, Paris, France
| | - Michel Lanteri-Minet
- Université Cote d’Azur, FHU INOVPAIN, CHU de Nice, Nice, France
- INSERM/UdA, U1107, Neuro-Dol, Auvergne University, Clermont-Ferrand, France
- Pain Department, CHU de Nice, Université Cote d’Azur, Nice, France
| |
Collapse
|
39
|
Mandonnet E, Wager M, Almairac F, Baron MH, Blonski M, Freyschlag CF, Barone F, Fontaine D, Pallud J, Hegi M, Viegas C, Zetterling M, Spena G, Goodden J, Rutten GJ, Taillandier L, Foroglu N, Darlix A, Skrap M, Martino J, von Campe G, Madadaki C, Gayat E, de Witt Hamer P, Gil Robles S, Sarubbo S, Santorius T, Bello L, Forster MT, Duffau H. Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step? Neurooncol Pract 2017; 4:241-247. [PMID: 31386020 PMCID: PMC6655513 DOI: 10.1093/nop/npw031] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Diffuse low-grade glioma form a rare entity affecting young people. Despite advances in surgery, chemotherapy, and radiation therapy, diffuse low-grade glioma are still incurable. According to current guidelines, maximum safe resection, when feasible, is the first line of treatment. Apart from surgery, all other treatment modalities (temozolomide, procarbazine-CCNU-vincristine regimen, and radiation therapy) are handled very differently among different teams, and this in spite of recent results of several phase 3 studies. Based on a European survey, this paper aimed to get a picture of this heterogeneity in diffuse low-grade glioma management, to identify clinically relevant questions raised by this heterogeneity of practice, and to propose new methodological frameworks to address these questions.
Collapse
Affiliation(s)
- Emmanuel Mandonnet
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Michel Wager
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Fabien Almairac
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Marie-Helene Baron
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Marie Blonski
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Christian F Freyschlag
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Fabio Barone
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Denys Fontaine
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Johan Pallud
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Monika Hegi
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Catarina Viegas
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Maria Zetterling
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Giannantonio Spena
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - John Goodden
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Geert-Jan Rutten
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Luc Taillandier
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Nicolas Foroglu
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Amélie Darlix
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Miran Skrap
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Juan Martino
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Gord von Campe
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Caterina Madadaki
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Etienne Gayat
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Philip de Witt Hamer
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Santiago Gil Robles
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Silvio Sarubbo
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Thomas Santorius
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Lorenzo Bello
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Marie-Therese Forster
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| | - Hugues Duffau
- Department of Neurosurgery, Lariboisière Hospital, APHP, Paris, France (E.M.); University Paris 7, Paris, France (E.M.); IMNC UMR8165, Orsay, France (E.M.); Department of Neurosurgery, Poitiers University Hospital, INSERM U1084, Poitiers, France (M.W.); Department of Neurosurgery, Hôpital Pasteur II, University Hospital of Nice, Nice, France (F.A., D.F.); Department of Radiotherapy, CHU of Besançon, Besançon, France (M.H.B.); Department of Neurooncology, Nancy neurological hospital, Nancy, France (M.B., L.T.); Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria (C.F.F.); Department of Neurosurgery & Gamma Knife, Cannizzaro General Hospital, Catania, Italy (F.B.); Department of Neurosurgery, Saint-Anne Hospital, Paris, France (J.P.); Neuroscience Research Center, Lausanne University Hospital, Lausanne, Switzerland (M.H.); Department of Neurosurgery, Hospital Garcia de Orta, Almada, Portugal (C.V.); Department of Neurosurgery, Uppsala University Hospital, Uppsala, Sweden (M.Z.); Department of Neurosurgery, Spedali Civili and University of Brescia, Brescia, Italy (G.S.); Leeds General Infirmary, Leeds, UK (J.G.); Department of Neurosurgery, St Elisabeth Hospital, The Netherlands (G.J.R.); Neurosurgical Department of Aristotelian University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece (N.F.); Department of Medical Oncology, Institut régional du Cancer de Montpellier ICM, Montpellier, France (A.D.); Department of Neurosurgery, Azienda ospedaliero – universitaria SMM, Udine, Italy (M.S.); Department of Neurological Surgery, Hospital Universitario Marqués de Valdecilla and Fundación Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.); Department of Neurosurgery, Medical University of Graz, Graz, Austria (G.V.C.); Department of Anesthesiology, Lariboisière hospital, APHP, Paris, France (C.M., E.G.); VU University Medical Center, Amsterdam, Netherlands (P.D.W.H.); Department of Neurosurgery, Hospital Quiron, Madrid, Spain (S.G.B.); Instituto de Investigacion BIOCRUCES, Bilbao, Spain (S.G.B.); Department of Neurosciences, Division of Neurosurgery, Structural and Functional Connectivity Lab Project, ‘S. Chiara’ Hospital, Trento, Italy (S.S.); Department of Neurosurgery, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK (T.S.); Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy (L.B.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (M.T.F.); Department of Neurosurgery, Hôpital Gui de Chauliac, Montpellier Medical University Center, Montpellier (H.D.)
| |
Collapse
|
40
|
Tardy MP, Gal J, Chamorey E, Almairac F, Vandenbos F, Bondiau PY, Saada-Bouzid E. Quality of Randomized Controlled Trials Reporting in the Treatment of Adult Patients with High-Grade Gliomas. Oncologist 2017; 23:337-345. [PMID: 29133516 DOI: 10.1634/theoncologist.2017-0196] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 09/26/2017] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND The randomized controlled trial (RCT) is the gold standard to objectively assess the effect of treatments. To help improve the quality of RCTs, experts established a list of recommendations, the CONsolidated Standards of Reporting Trials (CONSORT) Statement. In this study, we evaluated the implementation of the CONSORT Statement in the field of high-grade gliomas in adult patients and looked for criteria associated with higher quality of RCTs. MATERIALS AND METHODS We searched all high-grade gliomas RCTs published in PubMed between January 1990 and December 2016. The quality of these RCTs was assessed by completing a modified CONSORT Score (CS). RESULTS Ninety-six published RCTs were identified. The median CS was 19.5 on a scale of 0-33. Items were not equally reported. Items regarding the method of randomization or the blinding were reported in less than 25% of RCTs. However, the CS has constantly improved over the years. Before the implementation of the CONSORT Statement in 1996, the median CS was 13, whereas it was 17 for the period 1996-2004 and 22 after 2005. A higher CS was observed when RCTs were published in a journal with an impact factor above 10 (p < .001) or after 2010 (p = .001), when the primary outcome was clearly defined (p < .001) and for RCTs that enrolled more than 200 patients (p = .004). CONCLUSION Although there has been a steady improvement in the CS over the years in the field of high-grade gliomas, a major effort must be made in the reporting methods for randomization and blinding. IMPLICATIONS FOR PRACTICE This study showed that the quality of reporting of randomized control trials (RCTs) concerning the treatment of high-grade gliomas is poor. Factors associated with a better quality of reports were identified and should be incorporated into the design of future RCTs. When clinicians read the results of RCTs, they should be aware of the possible inadequate reporting from these trials and take it into account for the management of their patients. This study identifies how RCTs can be improved in their reporting but also in their design, in order to advance care for patients with high-grade gliomas in the future.
Collapse
Affiliation(s)
- Magalie P Tardy
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - Jocelyn Gal
- Department of Biostatistics, Centre Antoine Lacassagne, Nice, France
| | - Emmanuel Chamorey
- Department of Biostatistics, Centre Antoine Lacassagne, Nice, France
| | - Fabien Almairac
- Department of Neurosurgery, Pasteur II University Hospital, Nice, France
| | - Fanny Vandenbos
- Central Laboratory of Pathology, Pasteur I University Hospital, Nice, France
| | - Pierre-Yves Bondiau
- Radiotherapy, Cancer Research Center, Centre Antoine Lacassagne, Nice, France
| | - Esma Saada-Bouzid
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| |
Collapse
|
41
|
Dadone-Montaudié B, Ambrosetti D, Dufour M, Darcourt J, Almairac F, Coyne J, Virolle T, Humbert O, Burel-Vandenbos F. [18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression. PLoS One 2017; 12:e0184625. [PMID: 28937983 PMCID: PMC5609741 DOI: 10.1371/journal.pone.0184625] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2017] [Accepted: 08/28/2017] [Indexed: 11/18/2022] Open
Abstract
[18F]-FDOPA is a labeled amino acid (AA) analog used for positron emission tomography (PET) which is gaining increasing interest in the evaluation of brain tumors (BT). The AA-transporter LAT1 has been shown to be involved in [18F]-FDOPA uptake. The aim of this study was to determine whether the [18F]-FDOPA uptake was correlated with level of LAT1 expression in BT. Twenty-eight BT (including 19 gliomas and 9 metastases) were investigated by [18F]-FDOPA-PET prior to surgery and by anti-LAT1 immunohistochemistry on surgical specimens. The quantitative [18F]-FDOPA measured parameters were SUVmax, SUVmean and SUVpeak. LAT1 expression was quantified using a score (0 to 400). A significant [18F]-FDOPA uptake was associated with a LAT1 score ≥ 100 (p = 0.02) but there was no linear correlation between intensity of [18F]-FDOPA uptake and score of LAT1 expression whatever the parameters considered. LAT1 expression alone is not sufficient to explain variation of intensity of [18F]-FDOPA uptake in BT.
Collapse
Affiliation(s)
- Bérengère Dadone-Montaudié
- Department of Pathology, University Hospital, Nice, France
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
| | - Damien Ambrosetti
- Department of Pathology, University Hospital, Nice, France
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
| | - Maxime Dufour
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
- Department of Nuclear Medicine, Centre Antoine Lacassagne, Nice, France
- TIRO–UMR E 4320, University of Nice-Sophia-Antipolis, Nice, France
| | - Jacques Darcourt
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
- Department of Nuclear Medicine, Centre Antoine Lacassagne, Nice, France
- TIRO–UMR E 4320, University of Nice-Sophia-Antipolis, Nice, France
| | - Fabien Almairac
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
- Department of Neurosurgery, University Hospital, Nice, France
- UMR CNRS 7277-UMR INSERM 1091, Institute of Biology Valrose, University of Nice-Sophia-Antipolis, Nice, France
| | - John Coyne
- Department of Pathology, University Hospital, Nice, France
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
| | - Thierry Virolle
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
- UMR CNRS 7277-UMR INSERM 1091, Institute of Biology Valrose, University of Nice-Sophia-Antipolis, Nice, France
| | - Olivier Humbert
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
- Department of Nuclear Medicine, Centre Antoine Lacassagne, Nice, France
- TIRO–UMR E 4320, University of Nice-Sophia-Antipolis, Nice, France
| | - Fanny Burel-Vandenbos
- Department of Pathology, University Hospital, Nice, France
- UCA, Université Côte d’Azur, Nice-Sophia-Antipolis, France
- UMR CNRS 7277-UMR INSERM 1091, Institute of Biology Valrose, University of Nice-Sophia-Antipolis, Nice, France
- * E-mail:
| |
Collapse
|
42
|
Debruyne DN, Turchi L, Burel-Vandenbos F, Fareh M, Almairac F, Virolle V, Figarella-Branger D, Baeza-Kallee N, Lagadec P, Kubiniek V, Paquis P, Fontaine D, Junier MP, Chneiweiss H, Virolle T. DOCK4 promotes loss of proliferation in glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster expression. Oncogene 2017; 37:241-254. [PMID: 28925399 DOI: 10.1038/onc.2017.323] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 07/20/2017] [Accepted: 07/28/2017] [Indexed: 12/21/2022]
Abstract
Glioblastomas (GBM) are lethal primitive brain tumours characterized by a strong intra-tumour heterogeneity. We observed in GBM tissues the coexistence of functionally divergent micro-territories either enriched in more differentiated and non-mitotic cells or in mitotic undifferentiated OLIG2 positive cells while sharing similar genomic abnormalities. Understanding the formation of such functionally divergent micro-territories in glioblastomas (GBM) is essential to comprehend GBM biogenesis, plasticity and to develop therapies. Here we report an unexpected anti-proliferative role of beta-catenin in non-mitotic differentiated GBM cells. By cell type specific stimulation of miR-302, which directly represses cyclin D1 and stemness features, beta-catenin is capable to change its known proliferative function. Nuclear beta-catenin accumulation in non-mitotic cells is due to a feed forward mechanism between DOCK4 and beta-catenin, allowed by increased GSK3-beta activity. DOCK4 over expression suppresses selfrenewal and tumorigenicity of GBM stem-like cells. Accordingly in the frame of GBM median of survival, increased level of DOCK4 predicts improved patient survival.
Collapse
Affiliation(s)
- D N Debruyne
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France
| | - L Turchi
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France.,Service de Neurchirurgie, Hôpital Pasteur, CHU de Nice, France
| | - F Burel-Vandenbos
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France.,Service d'Anatomopathologie, Hôpital Pasteur, CHU de Nice, France
| | - M Fareh
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France
| | - F Almairac
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France.,Service de Neurchirurgie, Hôpital Pasteur, CHU de Nice, France
| | - V Virolle
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France
| | - D Figarella-Branger
- Aix Marseille Université, Faculté de Médecine de la Timone, Marseille, France.,CRO2, INSERM UMR 911, Marseille Cedex, France.,Departement de Pathology, CHU de la Timone, Marseille Cedex 5, France
| | - N Baeza-Kallee
- Aix Marseille Université, Faculté de Médecine de la Timone, Marseille, France.,CRO2, INSERM UMR 911, Marseille Cedex, France
| | - P Lagadec
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France
| | - V Kubiniek
- Laboratory of Solid Tumors Genetics, University Hospital of Nice, France
| | - P Paquis
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France.,Service de Neurchirurgie, Hôpital Pasteur, CHU de Nice, France
| | - D Fontaine
- Service de Neurchirurgie, Hôpital Pasteur, CHU de Nice, France
| | - M-P Junier
- CNRS UMR8246 Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris France.,Inserm U1130, Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris France.,University Pierre and Marie Curie UMCR18, Neuroscience Paris Seine - IBPS; Team Glial, Plasticity; 7 quai Saint-Bernard Paris France
| | - H Chneiweiss
- CNRS UMR8246 Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris France.,Inserm U1130, Neuroscience Paris Seine - IBPS; Team Glial Plasticity; 7 quai Saint-Bernard, Paris France.,University Pierre and Marie Curie UMCR18, Neuroscience Paris Seine - IBPS; Team Glial, Plasticity; 7 quai Saint-Bernard Paris France
| | - T Virolle
- Université Côte d'Azur, Nice, France.,CNRS, UMR7277, Nice, France.,Inserm, U1091, Nice, France
| |
Collapse
|
43
|
Fontaine D, Almairac F. Pain during awake craniotomy for brain tumor resection. Incidence, causes, consequences and management. Neurochirurgie 2017; 63:204-207. [DOI: 10.1016/j.neuchi.2016.08.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 08/01/2016] [Accepted: 08/22/2016] [Indexed: 10/20/2022]
|
44
|
Tardy MP, Gal J, Chamorey E, Almairac F, Van den bos F, Bondiau P, Saada-Bouzid E. P09.58 Quality of randomized controlled trials reporting in the treatment of adult high grade gliomas. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Joly H, Bourg V, Fontaine D, Almairac F, Mondot L, Lebrun-Frénay C. Suivi peri-opératoire et longitudinal de la mémoire de travail dans les gliomes de bas grade. Rev Neurol (Paris) 2017. [DOI: 10.1016/j.neurol.2017.01.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Spena G, Schucht P, Seidel K, Rutten GJ, Freyschlag CF, D'Agata F, Costi E, Zappa F, Fontanella M, Fontaine D, Almairac F, Cavallo M, De Bonis P, Conesa G, Foroglou N, Gil-Robles S, Mandonnet E, Martino J, Picht T, Viegas C, Wager M, Pallud J. Brain tumors in eloquent areas: A European multicenter survey of intraoperative mapping techniques, intraoperative seizures occurrence, and antiepileptic drug prophylaxis. Neurosurg Rev 2016; 40:287-298. [PMID: 27481498 DOI: 10.1007/s10143-016-0771-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2016] [Revised: 07/05/2016] [Accepted: 07/25/2016] [Indexed: 01/08/2023]
Abstract
Intraoperative mapping and monitoring techniques for eloquent area tumors are routinely used world wide. Very few data are available regarding mapping and monitoring methods and preferences, intraoperative seizures occurrence and perioperative antiepileptic drug management. A questionnaire was sent to 20 European centers with experience in intraoperative mapping or neurophysiological monitoring for the treatment of eloquent area tumors. Fifteen centers returned the completed questionnaires. Data was available on 2098 patients. 863 patients (41.1%) were operated on through awake surgery and intraoperative mapping, while 1235 patients (58.8%) received asleep surgery and intraoperative electrophysiological monitoring or mapping. There was great heterogeneity between centers with some totally AW oriented (up to 100%) and other almost totally ASL oriented (up to 92%) (31% SD). For awake surgery, 79.9% centers preferred an asleep-awake-asleep anesthesia protocol. Only 53.3% of the centers used ECoG or transcutaneous EEG. The incidence of intraoperative seizures varied significantly between centers, ranging from 2.5% to 54% (p < 0.001). It there appears to be a statistically significant link between the mastery of mapping technique and the risk of intraoperative seizures. Moreover, history of preoperative seizures can significantly increase the risk of intraoperative seizures (p < 0.001). Intraoperative seizures occurrence was similar in patients with or without perioperative drugs (12% vs. 12%, p = 0.2). This is the first European survey to assess intraoperative functional mapping and monitoring protocols and the management of peri- and intraoperative seizures. This data can help identify specific aspects that need to be investigated in prospective and controlled studies.
Collapse
Affiliation(s)
- Giannantonio Spena
- Clinic of Neurosurgery, Spedali Civili di Brescia, Scala 7, Piano 3°, Piazzale Spedali Civili 1, 25121, Brescia, Italy.
| | | | | | | | | | | | - Emanule Costi
- Clinic of Neurosurgery, Spedali Civili di Brescia, Scala 7, Piano 3°, Piazzale Spedali Civili 1, 25121, Brescia, Italy
| | - Francesca Zappa
- Clinic of Neurosurgery, Spedali Civili di Brescia, Scala 7, Piano 3°, Piazzale Spedali Civili 1, 25121, Brescia, Italy
| | - Marco Fontanella
- Clinic of Neurosurgery, Spedali Civili di Brescia, Scala 7, Piano 3°, Piazzale Spedali Civili 1, 25121, Brescia, Italy
| | - Denys Fontaine
- Neurosurgery, Centre Hospitalier Universitaire de Nice, Nice, France
| | - Fabien Almairac
- Neurosurgery, Centre Hospitalier Universitaire de Nice, Nice, France
| | | | | | | | - Nicholas Foroglou
- Neurosurgery, AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece
| | | | | | - Juan Martino
- Neurosurgery, Hospital Universitario Marques de Valdecilla, Santander, Spain
| | - Thomas Picht
- Neurosurgery, Charité Universitätsmedizin Berlin, Berlin, Germany
| | | | - Michel Wager
- Neurosurgery, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Johan Pallud
- Neurosurgery, Centre Hospitalier Sainte-Anne and Paris Descartes University, Paris, France
| |
Collapse
|
47
|
Gennari A, Almairac F, Litrico S, Albert C, Marty P, Paquis P. Spinal cord compression due to a primary vertebral hydatid disease: A rare case report in metropolitan France and a literature review. Neurochirurgie 2016; 62:226-8. [DOI: 10.1016/j.neuchi.2016.03.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Revised: 03/22/2016] [Accepted: 03/28/2016] [Indexed: 10/21/2022]
|
48
|
Burel-Vandenbos F, Ngo-Mai M, Dadone B, Di Mauro I, Gimet S, Saada-Bouzid E, Bourg V, Almairac F, Fontaine D, Virolle T, Pedeutour F. MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma. Neuropathol Appl Neurobiol 2016; 43:252-266. [PMID: 26946354 DOI: 10.1111/nan.12320] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 02/26/2016] [Accepted: 03/04/2016] [Indexed: 01/25/2023]
Abstract
AIMS MET gene amplification is rare in glioblastoma (GBM) and represents a potential target for MET inhibitors. An immunohistochemical screening may be useful to identify MET amplification. The aim of our study was to establish how MET immunolabelling correlates with MET amplification. METHODS Three cohorts including 108 GBM (cohort 1, prospective), 104 GBM (cohort 2, retrospective) and 52 GBM (cohort 3, prospective) were investigated for MET expression by immunohistochemistry. MET amplification was assessed by comparative genomic hybridization on microarray (CGH-array) in all cohorts and by fluorescent in situ hybridization (FISH) in cohorts 2 and 3. Active form of MET was assessed using p-MET (Y1349) immunohistochemistry. RESULTS Diffuse MET amplification detectable by CGH-array was associated with diffuse, strong MET immunolabelling (four cases in cohort 1 and one case in cohort 2). Focal MET amplification detectable only by FISH was observed in small foci of strongly immunopositive cells in two GBM (cohort 2). In both cohorts, MET amplification was never detected in GBM devoid of strongly immunopositive cells. MET overexpression, observed in 23% of unamplified GBM, was associated with a predominant weak-to-moderate staining intensity and with necrosis (P < 0.005). p-MET was detected in all MET-amplified GBM and in perinecrotic areas of nonamplified GBM. A strong MET immunostaining intensity, at least focal and distant from necrosis, showed 100% sensitivity and 84% specificity for predicting MET amplification in cohort 3. CONCLUSIONS MET amplification is characterized by strongly immunopositive cells. Only GBM showing strong MET immunostaining is appropriate for the assessment of MET amplification.
Collapse
Affiliation(s)
- F Burel-Vandenbos
- Department of Pathology, University Hospital of Nice, Nice, France.,UMR CNRS 7277-UMR INSERM 1091, Institute of Biology Valrose, University of Nice, Nice, France
| | - M Ngo-Mai
- Department of Pathology, University Hospital of Nice, Nice, France
| | - B Dadone
- Department of Pathology, University Hospital of Nice, Nice, France
| | - I Di Mauro
- Laboratory of Solid Tumors Genetics, University Hospital of Nice, Nice, France.,Institute for Research on Cancer and Aging, Nice, France
| | - S Gimet
- Laboratory of Solid Tumors Genetics, University Hospital of Nice, Nice, France.,Institute for Research on Cancer and Aging, Nice, France
| | - E Saada-Bouzid
- Department of Oncology, Centre Antoine Lacassagne, Nice, France
| | - V Bourg
- Department of Neurology, University Hospital of Nice, Nice, France
| | - F Almairac
- UMR CNRS 7277-UMR INSERM 1091, Institute of Biology Valrose, University of Nice, Nice, France.,Department of Neurosurgery, University Hospital of Nice, Nice, France
| | - D Fontaine
- Department of Neurosurgery, University Hospital of Nice, Nice, France
| | - T Virolle
- UMR CNRS 7277-UMR INSERM 1091, Institute of Biology Valrose, University of Nice, Nice, France
| | - F Pedeutour
- Laboratory of Solid Tumors Genetics, University Hospital of Nice, Nice, France.,Institute for Research on Cancer and Aging, Nice, France
| |
Collapse
|
49
|
Sakakini N, Turchi L, Bergon A, Holota H, Rekima S, Lopez F, Paquis P, Almairac F, Fontaine D, Baeza-Kallee N, Van Obberghen-Schilling E, Junier MP, Chneiweiss H, Figarella-Branger D, Burel-Vandenbos F, Imbert J, Virolle T. A Positive Feed-forward Loop Associating EGR1 and PDGFA Promotes Proliferation and Self-renewal in Glioblastoma Stem Cells. J Biol Chem 2016; 291:10684-99. [PMID: 27002148 DOI: 10.1074/jbc.m116.720698] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Indexed: 01/06/2023] Open
Abstract
Glioblastomas are the most common primary brain tumors, highly vascularized, infiltrating, and resistant to current therapies. This cancer leads to a fatal outcome in less than 18 months. The aggressive behavior of glioblastomas, including resistance to current treatments and tumor recurrence, has been attributed to glioma stemlike/progenitor cells. The transcription factor EGR1 (early growth response 1), a member of a zinc finger transcription factor family, has been described as tumor suppressor in gliomas when ectopically overexpressed. Although EGR1 expression in human glioblastomas has been associated with patient survival, its precise location in tumor territories as well as its contribution to glioblastoma progression remain elusive. In the present study, we show that EGR1-expressing cells are more frequent in high grade gliomas where the nuclear expression of EGR1 is restricted to proliferating/progenitor cells. We show in primary cultures of glioma stemlike cells that EGR1 contributes to stemness marker expression and proliferation by orchestrating a PDGFA-dependent growth-stimulatory loop. In addition, we demonstrate that EGR1 acts as a positive regulator of several important genes, including SHH, GLI1, GLI2, and PDGFA, previously linked to the maintenance and proliferation of glioma stemlike cells.
Collapse
Affiliation(s)
- Nathalie Sakakini
- From the Université Nice Sophia Antipolis, CNRS, INSERM, iBV, 06108 Nice, France, INSERM, U1090, Transcriptomic and Genomic Marseille-Luminy/Technical Advances for Genomics and Clinics (TGML/TAGC), Marseille F-13009, France, UMR_S 1090, TGML/TAGC, Aix-Marseille Université, Marseille F-13009, France
| | - Laurent Turchi
- From the Université Nice Sophia Antipolis, CNRS, INSERM, iBV, 06108 Nice, France
| | - Aurélie Bergon
- INSERM, U1090, Transcriptomic and Genomic Marseille-Luminy/Technical Advances for Genomics and Clinics (TGML/TAGC), Marseille F-13009, France, UMR_S 1090, TGML/TAGC, Aix-Marseille Université, Marseille F-13009, France
| | - Hélène Holota
- INSERM, U1090, Transcriptomic and Genomic Marseille-Luminy/Technical Advances for Genomics and Clinics (TGML/TAGC), Marseille F-13009, France, UMR_S 1090, TGML/TAGC, Aix-Marseille Université, Marseille F-13009, France
| | - Samah Rekima
- From the Université Nice Sophia Antipolis, CNRS, INSERM, iBV, 06108 Nice, France
| | - Fabrice Lopez
- INSERM, U1090, Transcriptomic and Genomic Marseille-Luminy/Technical Advances for Genomics and Clinics (TGML/TAGC), Marseille F-13009, France, UMR_S 1090, TGML/TAGC, Aix-Marseille Université, Marseille F-13009, France
| | - Philipe Paquis
- From the Université Nice Sophia Antipolis, CNRS, INSERM, iBV, 06108 Nice, France, the Service de Neurchirurgie, Hôpital Pasteur, CHU de Nice, Nice 06107, France
| | - Fabien Almairac
- From the Université Nice Sophia Antipolis, CNRS, INSERM, iBV, 06108 Nice, France, the Service de Neurchirurgie, Hôpital Pasteur, CHU de Nice, Nice 06107, France
| | - Denys Fontaine
- the Service de Neurchirurgie, Hôpital Pasteur, CHU de Nice, Nice 06107, France
| | - Nathalie Baeza-Kallee
- Aix Marseille Université, Faculté de Médecine de la Timone, 13284 Marseille, France, CRO2, INSERM UMR 911, 13284 Marseille Cedex, France
| | | | - Marie-Pierre Junier
- CNRS UMR8246 Neuroscience Paris Seine-IBPS, Team Glial Plasticity, 7 Quai Saint-Bernard, Paris 75005, France, INSERM U1130, Neuroscience Paris Seine-IBPS, Team Glial Plasticity, 7 Quai Saint-Bernard, Paris 75005, France, and University Pierre and Marie Curie UMCR18, Neuroscience Paris Seine-IBPS, Team Glial Plasticity, 7 Quai Saint-Bernard, Paris 75005, France
| | - Hervé Chneiweiss
- CNRS UMR8246 Neuroscience Paris Seine-IBPS, Team Glial Plasticity, 7 Quai Saint-Bernard, Paris 75005, France, INSERM U1130, Neuroscience Paris Seine-IBPS, Team Glial Plasticity, 7 Quai Saint-Bernard, Paris 75005, France, and University Pierre and Marie Curie UMCR18, Neuroscience Paris Seine-IBPS, Team Glial Plasticity, 7 Quai Saint-Bernard, Paris 75005, France
| | - Dominique Figarella-Branger
- Aix Marseille Université, Faculté de Médecine de la Timone, 13284 Marseille, France, CRO2, INSERM UMR 911, 13284 Marseille Cedex, France, the Departement de Pathology, CHU de la Timone, 13385 Marseille Cedex 5, France
| | - Fanny Burel-Vandenbos
- From the Université Nice Sophia Antipolis, CNRS, INSERM, iBV, 06108 Nice, France, the Service d'Anatomopathologie, Hôpital Pasteur, CHU de Nice, Nice 06107, France
| | - Jean Imbert
- INSERM, U1090, Transcriptomic and Genomic Marseille-Luminy/Technical Advances for Genomics and Clinics (TGML/TAGC), Marseille F-13009, France, UMR_S 1090, TGML/TAGC, Aix-Marseille Université, Marseille F-13009, France,
| | - Thierry Virolle
- From the Université Nice Sophia Antipolis, CNRS, INSERM, iBV, 06108 Nice, France,
| |
Collapse
|
50
|
Herbet G, Lafargue G, Almairac F, Moritz-Gasser S, Bonnetblanc F, Duffau H. Disrupting the right pars opercularis with electrical stimulation frees the song: case report. J Neurosurg 2015; 123:1401-4. [DOI: 10.3171/2014.12.jns141829] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The authors report the first case of a strikingly unusual speech impairment evoked by intraoperative electrostimulation in a 36-year-old right-handed patient, a well-trained singer, who underwent awake surgery for a right fronto-temporo-insular low-grade glioma. Functionally disrupting the pars opercularis of the right inferior frontal gyrus led the patient to automatically switch from a speaking to a singing mode of language production. Given the central role of the right pars opercularis in the inhibitory control network, the authors propose that this finding may be interpreted as possible evidence for a competitive and independent neurocognitive subnetwork devoted to the melodically intoned articulation of words (normal language-based vs singing-based) in subjects with high expertise. From a more clinical perspective, such data may have implications for awake neurosurgery, especially to preserve the quality of life for singers.
Collapse
Affiliation(s)
- Guillaume Herbet
- 1Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier
- 2Institute for Neuroscience of Montpellier, INSERM 1051, Team “Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors,” Saint Eloi Hospital, Montpellier University Medical Center, Montpellier
- 3University of Montpellier 1, Montpellier
| | - Gilles Lafargue
- 4Functional Neuroscience and Pathologies Lab, EA-4559, Université Lille Nord de France, Loos
| | | | - Sylvie Moritz-Gasser
- 2Institute for Neuroscience of Montpellier, INSERM 1051, Team “Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors,” Saint Eloi Hospital, Montpellier University Medical Center, Montpellier
| | - François Bonnetblanc
- 6INRIA, University of Montpellier 2, LIRMM, équipe DEMAR, Montpellier
- 7Cognition, Action et Plasticité Sensorimotrice, INSERM U-1093, Université de Bourgogne, UFR STAPS, Dijon; and
- 8Institut Universitaire de France, Paris, France
| | - Hugues Duffau
- 1Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier
- 2Institute for Neuroscience of Montpellier, INSERM 1051, Team “Plasticity of Central Nervous System, Human Stem Cells and Glial Tumors,” Saint Eloi Hospital, Montpellier University Medical Center, Montpellier
| |
Collapse
|